Novel routes of hydroperoxide detoxification

in *Mycobacterium tuberculosis*

Von der Gemeinsamen Naturwissenschaftlichen Fakultät
der Technischen Universität Carolo-Wilhelmina
zu Braunschweig

zur Erlangung des Grades eines
Doktors der Naturwissenschaften
( Dr. rer. nat. )

genehmigte

D i s s e r t a t i o n

von

Timo Jäger

aus Gießen
1. Referent: Prof. Dr. Dr. h.c. Leopold Flohé
2. Referent: Prof. Dr. Mahavir Singh
eingereicht am: 30.06.2003
mündliche Prüfung am: 03.09.2003
Druckjahr: 2003
Vorveröffentlichungen der Dissertation

Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Gemeinsamen Naturwissenschaftlichen Fakultät, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen vorab veröffentlicht:

Tagungsbeiträge


nach Einreichung der Dissertation:

# Table of contents

## 1 Introduction

1.1 Epidemiology .............................................................. 1  
1.2 Infection and disease ....................................................... 4  
1.3 The intracellular lifestyle of *M. tuberculosis* ......................... 7  
1.4 Drug-resistant tuberculosis ............................................. 8  
1.5 Oxidative stress response in *M. tuberculosis* ......................... 10  
1.6 The peroxiredoxin family ............................................ 11  
1.7 Objectives of the study .................................................. 15  

## 2 Materials and Methods .................................................. 16

2.1 Chemicals and reagents .................................................. 16  
2.2 Bacterial strains, plasmids and culture procedures ..................... 16  
2.2.1 Strains ....................................................................... 16  
2.2.1.1 *E. coli* strains .................................................. 16  
2.2.1.2 *Mycobacterium* strains ......................................... 17  
2.2.1.3 Plasmids .................................................................. 18  
2.2.2 Cultivation of *E. coli* .................................................. 18  
2.2.3 Cultivation of mycobacteria ............................................. 19  
2.3 General methods of molecular biology .................................... 20  
2.3.1 Electrotransformation in *E. coli* ................................... 20  
2.3.2 Electrotransformation in *M. smegmatis* .............................. 21  
2.3.3 Preparation of plasmid DNA .......................................... 21  
2.3.4 Purification of genomic DNA from mycobacteria .................. 21  
2.3.5 Enzymatic DNA restriction ........................................... 21
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.6</td>
<td>Ligation</td>
<td>22</td>
</tr>
<tr>
<td>2.3.7</td>
<td>Agarose gel electrophoresis of DNA</td>
<td>22</td>
</tr>
<tr>
<td>2.3.8</td>
<td>DNA extraction from agarose gels</td>
<td>22</td>
</tr>
<tr>
<td>2.3.9</td>
<td>Ethanol precipitation of DNA</td>
<td>23</td>
</tr>
<tr>
<td>2.3.10</td>
<td>Quantification of DNA</td>
<td>23</td>
</tr>
<tr>
<td>2.3.10.1</td>
<td>Absorbance measurement</td>
<td>23</td>
</tr>
<tr>
<td>2.3.10.2</td>
<td>Quantification of nucleic acids in agarose gels</td>
<td>23</td>
</tr>
<tr>
<td>2.3.11</td>
<td>Oligonucleotides</td>
<td>23</td>
</tr>
<tr>
<td>2.3.12</td>
<td>Polymerase chain reaction (PCR)</td>
<td>24</td>
</tr>
<tr>
<td>2.3.13</td>
<td>DNA sequencing</td>
<td>25</td>
</tr>
<tr>
<td>2.4</td>
<td>Biochemical methods</td>
<td>26</td>
</tr>
<tr>
<td>2.4.1</td>
<td>SDS polyacrylamide gel electrophoresis (SDS-PAGE)</td>
<td>26</td>
</tr>
<tr>
<td>2.4.2</td>
<td>Coomassie staining</td>
<td>27</td>
</tr>
<tr>
<td>2.4.3</td>
<td>Determination of protein concentration</td>
<td>27</td>
</tr>
<tr>
<td>2.4.4</td>
<td>Ultra-filtration</td>
<td>27</td>
</tr>
<tr>
<td>2.4.5</td>
<td>N-terminal amino acid sequencing</td>
<td>28</td>
</tr>
<tr>
<td>2.4.6</td>
<td>Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry</td>
<td>28</td>
</tr>
<tr>
<td>2.4.7</td>
<td>Isolation of mycothiol</td>
<td>28</td>
</tr>
<tr>
<td>2.5</td>
<td>Expression and purification of recombinant proteins</td>
<td>29</td>
</tr>
<tr>
<td>2.5.1</td>
<td>Creation of a Master Seed Bank</td>
<td>29</td>
</tr>
<tr>
<td>2.5.2</td>
<td>Induced expression of recombinant proteins in E. coli</td>
<td>29</td>
</tr>
<tr>
<td>2.5.3</td>
<td>Induced expression of MtMycR in M. smegmatis</td>
<td>30</td>
</tr>
<tr>
<td>2.5.4</td>
<td>Cell disruption by sonication</td>
<td>31</td>
</tr>
<tr>
<td>2.5.5</td>
<td>Chromatographic methods</td>
<td>31</td>
</tr>
<tr>
<td>2.5.5.1</td>
<td>Nickel chelate chromatography</td>
<td>31</td>
</tr>
<tr>
<td>2.5.5.2</td>
<td>Anion exchange chromatography</td>
<td>32</td>
</tr>
</tbody>
</table>

**Table of contents**
# Table of contents

## 2.5.5.3 Hydrophobic interaction chromatography (HIC) ..................................32
## 2.5.5.4 Gel permeation ..................................................................................33
## 2.5.6 Estimation of the molecular size of native proteins .........................33
## 2.6 Electron microscopy studies ......................................................................34
## 2.7 Enzymatic assays ......................................................................................35
## 2.7.1 Insulin reduction assay ..........................................................................35
## 2.7.2 MycR assay ..........................................................................................35
## 2.7.3 AhpD assay ..........................................................................................35
## 2.7.4 AhpC and TPx assay .............................................................................36
## 2.7.5 Steady-state kinetics .............................................................................37
## 2.7.6 Stopped-flow kinetics ............................................................................38
## 2.7.6.1 Direct measurement of peroxynitrite reduction by *MtTPx* by stopped-flow technique ..............................................................38
## 2.7.6.2 Rate constant determination of peroxynitrite reduction by competition experiments .................................................................39
## 2.8 Molecular modeling ..................................................................................40
## 2.9 Computer analyses ..................................................................................40

## 3 Results ........................................................................................................41

### 3.1 Preparation of system components .....................................................41
### 3.2 Peroxide detoxification pathways .........................................................42
### 3.2.1 Attempt to reconstitute a mycothiol reductase system ....................42
### 3.2.2 Reconstitution of the AhpD-dependent AhpC system ......................43
### 3.2.3 A novel thioredoxin-dependent AhpC system ..................................43
### 3.2.4 Another novel thiol peroxidase system .............................................46
### 3.3 Kinetics and particularities .......................................................................47
### 3.3.1 The AhpD-dependent AhpC system ...............................................47
### 3.3.2 The thioredoxin-dependent AhpC system ........................................54
3.3.3 The thiol peroxidase systems .......................................................... 56
3.4 Specificity of \textit{Mt}AhpC and \textit{Mt}TPx for reactive oxygen and
nitrogen intermediates ........................................................................ 60

4 Discussion ......................................................................................... 64
4.1 AhpC and TPx: Members of the peroxiredoxin family ................. 65
4.2 AhpC and TPx homologues ............................................................. 67
4.3 Structural and conformational properties of \textit{Mt}AhpC and
\textit{Mt}TPx .......................................................................................... 68
4.4 Physiological relevance of the \textit{Mt}AhpC and \textit{Mt}TPx systems ....... 72
4.5 AhpC and TPx are potential drug targets ..................................... 75

5 Summary .......................................................................................... 77

6 References ........................................................................................ 78

7 Appendix .......................................................................................... 98
7.1 Abbreviations .................................................................................. 98
7.2 Abbreviations of nucleotides and amino acids ........................... 103
1 Introduction

*Mycobacterium tuberculosis* is a leading pathogen worldwide, infecting an estimated 8 million and killing 2 – 3 million people each year (Dye *et al.*, 1999). In addition, it is estimated that ~ 2 billion people have been exposed to *M. tuberculosis*, and thus are at risk of developing the active disease. Although most of the infected individuals reside in less industrialized countries, the rates of infection are also increasing at an alarming rate in areas undergoing rapid social change, such as the countries of the former Soviet Union (Keshavjee and Becerra, 2000). In part because of the symbiotic relationship between human immunodeficiency virus (HIV) and tuberculosis, and because of the increasingly rapid displacement of populations, the incidence of multi-drug-resistant (MDR) tuberculosis is an important worldwide concern. Thus, in a survey of 35 countries, 12.6 % of *M. tuberculosis* isolates were found to be resistant to at least one drug, and 2.2 % were resistant to both isoniazid and rifampicin, the two primary drugs used to treat tuberculosis (Pablos-Mendez *et al.*, 1998). This resurgence of tuberculosis has led to renewed efforts to find new drugs for the treatment of this dreaded disease, particularly agents that exhibit activity against drug-resistant strains, completely sterilize the infection, or shorten the duration of drug therapy and thus promote drug compliance.

1.1 Epidemiology

Tuberculosis (TB) is a worldwide public health problem and is usually transmitted by droplet infection. As noted previously, approximately one third of the earth’s population is infected with *M. tuberculosis*. Although less than ten per cent become sick, in 1995 more humans died of tuberculosis than ever before. An increasing drug resistance problem coupled with the HIV-
induced acquired immunodeficiency syndrome is leading to further epidemic spread among population. The common infectious agent is *M. tuberculosis*, more rarely *Mycobacterium bovis*, *Mycobacterium africanum*, *Mycobacterium microti*, and the newly discovered *Mycobacterium canettii* (Pfyffer et al., 1998; Am. Thorac. Soc., 2003). In about 85% of all clinical cases the lung is involved. However, with the increase of the HIV infections, the proportion of extra-pulmonary types is on the increase. In 1997, 8 million new TB cases were assessed, adding to 16 million cases already registered. Of the latter, approximately 2 million could have died since then (Dye et al., 1999). Some 80% of all patients were registered in 22 countries. More than half of them were from five nations belonging to the southeast region of Africa (Fig. 1.1). Not surprisingly, 9 out of 10 of the highest incidences are located in that continent (Dye et al., 1999). This situation is likely to deteriorate in the future. The World Health Organization (WHO) expects an increase of the annual disease rates from 8 million in 1997 to 10.2 million per year in 2005 (WHO, 2001). This alarming sign of the spreading of an endemic disease and the fact that drug resistant strains have emerged on a massive scale underscore the importance of studying mycobacterial defense mechanisms. Although scientific breakthroughs in the field have been rare, the release of the complete genome sequence of *M. tuberculosis* (Cole et al., 1998) has initiated a hunt for genes of interest for vaccine development, either as targets for gene knockout or as candidates for protective antigens.
Fig. 1.1: Tuberculosis (TB) notification rates and estimated TB incidence rates in 2000. The 202 countries reporting to WHO notified a total of 3,671,973 cases (61 per 100,000 population). This represents only one quarter (27 %) of the estimated total (WHO, 2002).
1.2 Infection and disease

Tuberculosis is caused by the acid-fast, rod shaped bacillus, *Mycobacterium tuberculosis*. The microorganism is shielded by a unique wax-rich cell wall that is composed of long-chain fatty acids, glycolipids and other components. Accordingly, approximately 250 genes within the *M. tuberculosis* genome are involved in the fatty-acid metabolism. The robust shell contributes to the capacity of *M. tuberculosis* to survive in host phagocytes. *M. tuberculosis* is a slow-growing organism, with a replication time of approximately 20 hours. This slow growth forms the basis for the chronic nature of infection and disease, complicates microbiological diagnosis and necessitates long-term drug treatment.

In clinical terms tuberculosis is divided into primary (I) and reactivated forms (II).

(I) The typical source of a primary infection is a person with pulmonary tuberculosis producing up to 3,000 aerosol droplets per cough attack (Fig. 1.2). A primary infection need not be fatal and can be treated with appropriate chemotherapy. However, on occasions (AIDS etc.) the illness will not stay localized but can progress and the person will suffer from secondary complications. Generally, incorporated mycobacteria can survive after phagocytosis by macrophages. To do so, they must be able to resist many cellular defense strategies in the human body: reactive oxygen species and nitrogen compounds as well as enzyme activities such as myeloperoxidases, phosphatases, hydrolases, proteases, lysozyme, and lipases. In particular, the lipid-rich cell wall plays an important role as protective layer against aggressive lysosomal factors and as a diffusion barrier against drugs.

(II) Reactivated tuberculosis is a recurrence of the pulmonary form after sensitization to *M. tuberculosis* during the primary infection: after an interval of
latency, a cellular immune response leads to the formation of tissue tumors (granuloma) (Fig. 1.2). These highly characteristic pathological lesions are also known as tubercles. Tissue destruction (fibrosis) presents focal areas with dead cells (necrosis), forming a friable and amorphous granular mass, cheese-like in appearance (caeseous detritus). Often these foci show spontaneous remission; otherwise they become calcified. However, on occasion such material is liberated into the bronchioles of the respiratory tract and is expectorated. Subsequently, the aspiration can cause inflammation of the lungs, known as tuberculous pneumonia. Alternatively, the material persists in cavities as encapsulated tuberculosis (Rubin and Farber, 1999).
Fig. 1.2: **Main features of tuberculosis: from infection to host defense.** There are three potential outcomes of infection of the human host in *M. tuberculosis*. a) The frequency of abortive infection resulting in spontaneous healing is unknown, but is assumed to be minute. b) In the immunocompromised host, disease can develop directly after infection. c) In most cases, mycobacteria are initially contained and disease develops later as a result of reactivation. The granuloma is the site of infection, persistence, pathology and protection. Effector T cells (including conventional CD4+ and CD8+ T cells, and unconventional T cells, such as γδ T cells, and double-negative or CD4/CD8 single-positive T cells that recognize antigen in the context of CD1) and macrophages participate in the control of tuberculosis. Interferon-γ (IFN-γ) and tumour-necrosis factor-α (TNF-α), produced by T cells, are important macrophage activators. Macrophage activation permits phagosomal maturation and the production of antimicrobial molecules such as reactive nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI). LT-α3, lymphotoxin-α3 (Kaufmann, 2001).
1.3 The intracellular lifestyle of *M. tuberculosis*

*M. tuberculosis* uses macrophages as its preferred habitat, which has two important implications for its survival (Schaible *et al.*, 1999). First, macrophages, as professional phagocytes, are endowed with several surface receptors that facilitate antigen uptake, thereby rendering specific host-invasion strategies dispensable (Ernst, 1998; Ehlers and Daffe, 1998). Cholesterol has been shown to act as a docking site for the pathogen, promoting receptor-ligand interactions (Gatfield and Pieters, 2000). The initial interaction with surface receptors influences the subsequent fate of *M. tuberculosis* within the macrophage. Interactions with the constant regions of immunoglobulin receptors and Toll-like receptors stimulate host-defense mechanisms, whereas those with complement receptors promote mycobacterial survival (Armstrong and Hart, 1975; Schorey *et al.*, 1997; Brightbill *et al.*, 1999; Thoma-Uszynski *et al.*, 2001). The second consequence, which warrants more sophisticated coping mechanisms, is the survival of *M. tuberculosis* within the phagosome, as this constitutes a harsh environment that is detrimental to many microbes (Schaible *et al.*, 1999). *M. tuberculosis* overcomes this obstacle by arresting the phagosome at an early stage of maturation, and by preventing fusion of the phagosome with lysosomes (Armstrong and Hart, 1975; Russell *et al.*, 1996; Harth and Horwitz, 1999; Ferrari *et al.*, 1999).

The arrest of phagosomal maturation is not an all-or-nothing event. Some mycobacterial phagosomes can proceed to develop to the more mature stages of the phagolysosome. Phagosomal maturation is promoted by activation with interferon-γ (IFN-γ), which stimulates anti-mycobacterial mechanisms in macrophages (Fig. 1.2), notably the formation of reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI) (Schaible *et al.*, 1998; Schaible *et al.*, 1999). However, even IFN-γ-activated macrophages fail to fully eradicate their resident *M. tuberculosis* (Kaufmann,
1999). Persistent microbes might proceed to a stage of dormancy with a reduced metabolic activity that facilitates their survival under conditions of nutrient and oxygen deprivation. These bacteria can persist without producing disease and therefore create a state of latency. Nevertheless, the risk of disease outbreak at a later time remains. *In vitro* experiments indicate that mycobacteria switch to lipid catabolism and nitrate respiration to ensure their survival (McKinney *et al.*, 2000; Weber *et al.*, 2000). Lipids are abundant in the caseous detritus of granulomas, providing a rich source of nutrients during persistence.

### 1.4 Drug-resistant tuberculosis

Most forms of drug resistance are iatrogenic by their nature, i.e. acquired during pharmacotherapy. The most common causes leading to the selection of drug-resistant strains among microorganisms are: (i) administration of a single drug (instead of a combination), (ii) sub-therapeutic dosage below the pharmacologically required minimum inhibiting concentration (MIC), (iii) treatment applied for too short a time period, (iv) non-compliance of patients, (v) socio-economical problems, circumstances under which poor people strive to obtain medical assistance, (vi) insufficient regional drug availability, and (vii) lack of dispensation facilities and professional pharmaceutical care (Crofton *et al.*, 1997).

A typical clinical case of drug resistant tuberculosis would be one of the pulmonary types, in which the patient spreads resistant bacilli. Resistance implies lack of any anti-infectious effects at least for the front line drugs (in decreasing or increasing order of efficiency or toxicity, respectively): isoniazid (isonicotinic acid hydrazide, INH), rifampicin (rifampin, RMP), pyrazinamide, ethambutol, and streptomycin. Second-line drugs are protonamide, ethionamide, thiacetazone, thiocarlide, cycloserine, capreomycine, and paraaminosalicylic acid. Those are all bacteriostatic in action whereas the
primary-line drugs are bactericidal. Overall, some form part of the recommended treatment for tuberculosis issued by the WHO. Due to the required administration of antituberculous agents for prolonged durations (several months to years), resistance has rapidly developed in 5 – 10 % of the strains (1 – 3 % multidrug resistant disease). To avoid selection of even more primarily resistant bacteria the WHO recommends a treatment scheme within their DOTS (Directly Observed Treatment Short-Course) program. That consists of a two-months treatment with a combination of 4 antibiotics including isoniazid, rifampicin, and pyrazinamide, complemented with either streptomycin or ethambutol. It is followed by a 6-months treatment with isoniazid, combined with either ethionamide or ethambutol, or a 4-months treatment with isoniazid and rifampicin (WHO, 1998; WHO, 1999).

Shortly after the introduction of isoniazid chemotherapy in 1952, mycobacteria resistant to that antituberculous agent were described (Middlebrook, 1952). Nevertheless, isoniazid has remained as the basic medication. The mode of action of isoniazid is not fully understood, but there is evidence that certain isoniazid-resistant strains of mycobacteria have reduced catalase/peroxidase (KatG) enzyme activity. It suggests that the antibiotic is acted upon by that enzyme and, therefore, isoniazid is a prodrug (Zhang et al., 1992; Johnsson and Schultz, 1994; Johnsson et al., 1995). Expression of KatG is a requirement for bacterial sensitivity to isoniazid (Zhang et al., 1992; Zhang et al., 1993). In its active form, isoniazid generates a range of reactive oxygen species and reactive organic radicals, which then attack multiple targets (DNA, carbohydrates, lipids) in the tubercle bacillus (Winder, 1982). The most well known target is the cell wall mycolic acid synthesis pathway (Winder and Collins, 1970; Banerjee et al., 1994; Mdluli et al., 1998). Mutations in $katG$, $inhA$ (acyl carrier protein- enoyl reductase), and $ndh$ (NADH dehydrogenase, resulting in an increased NADH/NAD$^+$ ratio), cause isoniazid resistance (Zhang et al., 1992; Banerjee et al., 1994; Lee et al., 2001). Point mutations or deletions in $katG$ are the most common
mechanism of isoniazid resistance in *M. tuberculosis* clinical isolates (Heym *et al.*, 1994; Musser, 1995; Musser *et al.*, 1996; Rouse *et al.*, 1996; Heym and Cole, 1997). Isolates most resistant to isoniazid tend to carry mutations that severely reduce or eliminate KatG-peroxidase activity, whereas *M. tuberculosis* mutants that retain some percent of peroxidase activity remain moderately resistant to isoniazid. In addition, introduction of *M. tuberculosis katG* into isoniazid-resistant mutants restores innate susceptibility to this drug (Zhang *et al.*, 1992; Zhang and Young, 1993; Heym *et al.*, 1995; Rouse and Morris, 1995).

1.5 Oxidative stress response in *M. tuberculosis*

In addition to its role in the activation of isoniazid, KatG is thought to play another key role in the infection with the tubercle bacillus. As intracellular pathogens capable of surviving and multiplying within host macrophages, mycobacteria have to survive exposure to macrophage killing mechanisms, including the oxidative stress response (see 1.3). The catalase/peroxidase KatG is a component of the bacterial OxyR response, which is induced by oxidative stress and protects the bacteria against oxidative killing (Storz *et al.*, 1990; Farr and Kogoma, 1991; Aslund *et al.*, 1999; Zahr and Deretic, 2002). Thus, the loss of a functional KatG in isoniazid-resistant strains of *M. tuberculosis* would be expected to lead to a reduced ability of the pathogen to survive within the intracellular environment; indeed it was reported many years ago that isoniazid resistance was associated with loss of virulence in the guinea pig (Middlebrook and Cohn, 1953).

It was found that the gene encoding the OxyR transcription factor of *M. tuberculosis* is defective as a result of a number of mutations, and with the exception of KatG, *M. tuberculosis* does not have a peroxide-inducible response (Sherman *et al.*, 1995; Deretic *et al.*, 1995). However, some isoniazid-resistant *katG* mutants compensate their loss of catalase/peroxidase ac-
tivity by overexpression of the alkyl hydroperoxide reductase AhpC (alkyl hydroperoxide reductase subunit C). Thus, it has been claimed that during infection with isoniazid-resistant, KatG-deficient *M. tuberculosis*, there is a selection for compensatory *ahpC* promoter mutations, enabling the organisms to grow intracellularly (Sherman *et al.*, 1996; Sherman *et al.*, 1999).

The mycobacterial *ahpC* gene encodes an orthologue of bacterial alkyl hydroperoxidases (Christman *et al.*, 1985; Jacobson *et al.*, 1989; Sherman *et al.*, 1996; Dhandayuthapani *et al.*, 1996; Sreevatsan *et al.*, 1997; Heym *et al.*, 1997; Wilson *et al.*, 1998; Pagan-Ramos *et al.*, 1998; Chen *et al.*, 1998; Cooper *et al.*, 2000; Springer *et al.*, 2001). In most mycobacteria, the *ahpC* gene is linked to *oxyR* and is activated by its gene product, an orthologue of the global regulator OxyR, controlling the peroxide stress. As mentioned previously, in *M. tuberculosis* as a species, and in all members of the *M. tuberculosis* complex, the *oxyR* gene is inactivated and represents a pseudo-gene. Recently it was shown that there exists a second level of *ahpC* regulation independent of *oxyR*. The *ahpC* gene is silenced in aerobic cultures of virulent *M. tuberculosis*, but is activated in statically grown organisms (Springer *et al.*, 2001; Master *et al.*, 2002). AhpC has been indirectly implicated in nitric oxide metabolism using expression in heterologous systems like *Salmonella* (Chen *et al.*, 1998). Purified AhpC has been shown to reduce hydroperoxides (Hillas *et al.*, 2000; Chauhan and Mande, 2001) and has also been suggested to have peroxynitrite reductase activity (Bryk *et al.*, 2000).

### 1.6 The peroxiredoxin family

The mycobacterial AhpC belongs to a family of bacterial and eukaryotic antioxidant proteins with alkyl hydroperoxidase (Ahp) and thioredoxin-dependent peroxidase (TPx) activities. The two are peroxiredoxin-type peroxidases. Peroxiredoxins (Prxs) are a new and expanding family of thiol-
specific antioxidant proteins, also termed the thioredoxin peroxidases and alkyl hydroperoxide reductase proteins (Chae et al., 1994a; Chae et al., 1994b; Schroeder and Ponting, 1998). Prxs exert their protective antioxidant role in cells through their peroxidase activity (ROOH + 2e\(^{-}\) → ROH + H\(_2\)O), whereby hydrogen peroxide, peroxynitrite and a wide range of organic hydroperoxides (ROOH) are reduced and detoxified (Jacobson et al., 1989; Poole and Ellis, 1996; Bryk et al., 2000; Peshenko and Shichi, 2001; Hofmann et al., 2002; Wood et al., 2003a). Peroxiredoxins are proteins without any prosthetic group. The only redox-active residues are cysteines. Their sequences classify them as a distinct protein family that is unrelated to any of the other peroxidase families. As a rule, the catalytic cycle of peroxiredoxins makes use of redox shuttling of one or two cysteine residues. These enzymes are truly ubiquitous having been identified in yeast, plant and animal cells, including both protozoan and helminth parasites, and most, if not all, eubacteria and archaea. Prxs are produced at high levels in cells (Moore et al., 1991; Link et al., 1997; Chae et al., 1999), and many organisms produce more than one isoform of Prx, including at least six Prxs identified in mammalian cells (Wood et al., 2003a). The high abundance of Prxs in a wide range of species and a recent finding that AhpC and not catalase is responsible for reduction of endogenously generated H\(_2\)O\(_2\) in *Escherichia coli* (Seaver and Imlay, 2001) provide a persuasive argument that Prxs are important players in peroxide detoxification in cells. In addition, Baker and Poole reported very recently, that *E. coli* thiol peroxidase (TPx), also a member of the Prx family, is part of an oxidative defense system that uses reducing equivalents from thioredoxin and thioredoxin reductase to reduce alkyl hydroperoxides (Baker and Poole, 2003), and *tpx* mutation studies in *Helicobacter pylori* showed that TPx plays a significant role in peroxide and superoxide resistance of *H. pylori* (Comtois et al., 2003).

In enterobacteria AhpC, together with the flavine-containing disulfide reductase AhpF (alkyl hydroperoxide reductase subunit F), forms a two-
component system achieving hydroperoxide reduction by NAD(P)H without the aid of auxiliary enzymes or low molecular weight redox mediators (Fig. 1.3; Jacobson et al., 1989; Storz et al., 1989). In E. coli and Salmonella typhimurium AhpF and AhpC are jointly regulated by the oxyR regulon that responds to oxidative stress and determines hydroperoxide resistance (Zahrt and Deretic, 2002). While AhpC appears to be ubiquitous in bacteria (Hofmann et al., 2002), AhpF is not. H. pylori lacks AhpF. Instead, H. pylori uses a thioredoxin (Trx) as the reductant of AhpC (Fig. 1.3) (Baker et al., 2001). In contrast to enterobacteria, M. tuberculosis does not respond to oxidative stress with overexpression of AhpC (Dhandayuthapani et al., 1996), but AhpC is constitutively overexpressed in isoniazid-resistant clinical isolates. The resistance to isoniazid is due to a deficiency of catalase, which is required to activate the drug (see 1.4 and 1.5). Also mycobacteria do not contain a functional AhpF. That indicates that M. tuberculosis normally relies on catalase for H₂O₂ detoxification but depends on AhpC if catalase is missing.
**Fig. 1.3: Examples of bacterial antioxidant defense systems.** Homologous proteins are shown in identically coloured circles. *H. pylori* makes use of the Trx-system for reduction of Prx-type AhpC like mammals and many other organisms. In enterobacteria AhpC is directly reduced by a flavin-dependent disulfide reductase. In mycobacteria AhpC reduction appears to be linked to energy metabolism. They also contain a thioredoxin system, further glutaredoxin-like proteins and mycothiol as low molecular weight redox mediator. The role of these redox systems in antioxidant defense is still unclear (Budde and Flohé, 2002). AhpC, alkyl hydroperoxide reductase subunit C; AhpD, alkyl hydroperoxide reductase subunit D; AhpF, alkyl hydroperoxide reductase subunit F; Lpd, dihydrolipoamide dehydrogenase; MycR, mycothiol reductase; MSH, mycothiol; SucB, dihydrolipoamide succinyltransferase; Trx, thioredoxin; TrxR, thioredoxin reductase
1.7 Objectives of the study

At the beginning of this thesis it was unclear how AhpC is reduced in mycobacteria. Attempts to substitute the missing AhpF by homologous mycothiol reductase and mycothiol or a thioredoxin/thioredoxin reductase system have failed so far (Hillas et al., 2000; Vergauwen et al., 2001). More recently, a quite unique link of AhpC to mycobacterial energy metabolism was proposed (Bryk et al., 2002): The reduction equivalents are transferred by two components of the α-keto acid dehydrogenase complex [dihydrolipoamide dehydrogenase (Lpd) and dihydrolipoamide succinyltransferase (SucB)] to AhpD (alkyl hydroperoxide reductase subunit D) that, like thioredoxins, contains a CXXC motif and thus substitutes for a real thioredoxin in AhpC reduction. The low molecular weight thiol that often mediates the flux from the flavoproteins to CXXC proteins is replaced here by SucB-bound lipoic acid (Fig. 1.3).

The objectives of this study were to:

- search for more likely metabolic partner of the mycobacterial AhpC,
- screen the genome of M. tuberculosis (Cole et al., 1998) for homologues of AhpF, thioredoxin-related proteins and peroxiredoxins,
- express the genes heterologously, and
- attempt to reconstitute peroxidase systems from the isolated gene products in vitro and examine their efficiencies by kinetic analysis.
2 Materials and Methods

2.1 Chemicals and reagents

Most of the chemicals purchased were of the highest purity grade available and were from:

- J. T. Baker B. V., Deventer, Netherlands
- Merck, Darmstadt, Germany
- Serva Electrophoresis, Heidelberg, Germany
- Sigma-Aldrich, Taufenkirchen, Germany
- Roche, Mannheim, Germany

2.2 Bacterial strains, plasmids and culture procedures

2.2.1 Strains

2.2.1.1 E. coli strains

The E. coli strains used in this study and their characteristics are listed in Table 2.1. All strains were grown in LB medium or on LB agar (see Table 2.3).
Table 2.1: *E. coli* strains and their characteristics

<table>
<thead>
<tr>
<th>strain</th>
<th>genotype and relevant phenotype</th>
<th>origin / reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em> DH5α</td>
<td>supE44 ΔlacU169(Φ80 lacZ ΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1</td>
<td>(Hanahan, 1983)</td>
</tr>
<tr>
<td><em>E. coli</em> BL21 (DE3)</td>
<td>F’ ompT hsdS&lt;sub&gt;B&lt;/sub&gt; (r&lt;sub&gt;B&lt;/sub&gt; m&lt;sub&gt;B&lt;/sub&gt;) gal dcm (DE3)</td>
<td>Novagen (Madison, USA)</td>
</tr>
<tr>
<td><em>E. coli</em> Tuner (DE3)</td>
<td>F’ ompT hsdS&lt;sub&gt;B&lt;/sub&gt; (r&lt;sub&gt;B&lt;/sub&gt; m&lt;sub&gt;B&lt;/sub&gt;) gal dcm lacY1 (DE3)</td>
<td>Novagen (Madison, USA)</td>
</tr>
</tbody>
</table>

2.2.1.2 *Mycobacterium* strains

All *mycobacterium* strains used in this study are listed in Table 2.2. The *M. bovis* BCG and *M. marinum* strains were purchased from the Statens Serum Institut (Copenhagen, Denmark) and the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany), respectively. Cell lysates from *M. tuberculosis* were kindly provided by Clara Espitia (Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico).

Table 2.2: *Mycobacterium* strains and their origin

<table>
<thead>
<tr>
<th>strain</th>
<th>code / ATCC no.</th>
<th>origin</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>M. bovis</em> BCG Chicago; DSMZ 43990</td>
<td>ATCC 27289</td>
<td>DSMZ, Braunschweig, Germany</td>
</tr>
<tr>
<td><em>M. bovis</em> BCG Copenhagen</td>
<td>Danish strain 1331</td>
<td>Statens Serum Institut, Copenhagen, Denmark</td>
</tr>
<tr>
<td><em>M. marinum</em>; DSMZ 44344</td>
<td>ATCC 927</td>
<td>DSMZ, Braunschweig, Germany</td>
</tr>
<tr>
<td><em>M. marinum</em>; DSMZ 44345</td>
<td>ATCC 11567</td>
<td>DSMZ, Braunschweig, Germany</td>
</tr>
<tr>
<td><em>M. tuberculosis</em> H37Rv</td>
<td>ATCC 25618</td>
<td>C. Espitia, Mexico City, Mexico</td>
</tr>
</tbody>
</table>
2.2.1.3 Plasmids

For cloning and heterologous expression the *E. coli* expression vector pET22b(+) (Novagen, Madison, USA) was used. This 5.5 kb vector carries an N-terminal *pelB* signal sequence for potential periplasmic localization, T7 promoter and terminator, lac operator, pBR322 ori, ampicillin resistance plus optional C-terminal His-tag and is IPTG inducible. The vector pTrcHis A (Invitrogen, Karlsruhe, Germany) containing the mycobacterial thioredoxin reductase open reading frame (ORF) fused to an N-terminal 6xHis-tag was kindly provided by T. H. M. Ottenhoff (Leiden University Medical Centre, Leiden, Netherlands).

For cloning and expression in mycobacteria the plasmid pMV261 was kindly provided by Clara Espitia (Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico). This shuttle plasmid is a 4.5 kb extrachromosomal plasmid designed to express foreign polypeptides as fusion proteins with mycobacterial HSP60. A multicloning site is present after the sixth codon of the HSP60 gene, and expression is under the control of the HSP60 promoter. The *aph* gene from Tn903 confers kanamycin resistance. Origins of replication from *E. coli* pUC19 and mycobacterial pAL5000 are also present (Stover *et al.*, 1991).

2.2.2 Cultivation of *E. coli*

The *E. coli* strain DH5α was used for plasmid transformation and replication. The strains BL21 (DE3) and Tuner (DE3) were used for heterologous expression of recombinant proteins. Cultural conditions were 30 °C – 37 °C in LB (Luria-Bertani) medium (Table 2.3) with moderate shaking. For recombinant *E. coli* strains selection was performed by addition of 200 µg/ml ampicillin to the medium. Bacterial stocks were prepared from a single colony and stored at -80 °C in LB broth containing 50 % (v/v) glycerol.
Table 2.3: Composition of Luria-Bertani (LB) medium

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacto-Tryptone (Becton Dickinson (BD), Heidelberg, Germany)</td>
<td>10 g/1000 ml</td>
</tr>
<tr>
<td>Bacto-Yeast extract (BD, Heidelberg, Germany)</td>
<td>5 g/1000 ml</td>
</tr>
<tr>
<td>sodium chloride p.a.</td>
<td>10 g/1000 ml</td>
</tr>
</tbody>
</table>

The pH was adjusted to pH 7.4 with 1 M NaOH. For the preparation of LB agar plates 1.5 % (w/v) Bacto-Agar (BD, Heidelberg, Germany) was added.

2.2.3 Cultivation of mycobacteria

Culture conditions for *M. bovis* BCG and *M. smegmatis* were 37 °C in Middlebrook 7H9 liquid medium or on Middlebrook 7H10 agar (Table 2.4) with moderate shaking of the liquid medium. For recombinant *M. smegmatis* selection was performed by addition of 50 µg/ml kanamycin to the medium. Bacterial stocks were prepared from a single colony and stored at -80 °C in Middlebrook 7H9 broth containing 50 % (v/v) glycerol.

The cultures were frequently tested for contamination by acid fast staining using the ACCUSTAIN Kit (Sigma-Aldrich, Taufenkirchen, Germany).

Table 2.4: Composition of Middlebrook 7H9 medium and 7H10 agar

<table>
<thead>
<tr>
<th>Middlebrook 7H9 medium:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacto-Middlebrook 7H9 Broth (BD, Heidelberg, Germany)</td>
</tr>
<tr>
<td>glycerol (87 % (w/v))</td>
</tr>
<tr>
<td>Tween 80</td>
</tr>
<tr>
<td>Bacto-Middlebrook ADC Enrichment (BD, Heidelberg, Germany)</td>
</tr>
</tbody>
</table>

Middlebrook 7H10 agar:

| Bacto-Middlebrook 7H10 Agar Base (BD, Heidelberg, Germany) | 19 g/1000 ml |
| glycerol (87 % (w/v)) | 5 ml/1000 ml |
| Bacto-Middlebrook OADC Enrichment (BD, Heidelberg, Germany) | 100 ml/1000 ml |
2.3 **General methods of molecular biology**

Standard molecular biology methods were used, essentially according to Sambrook *et al.* (2001).

2.3.1 **Electrotransformation in *E. coli***

Electroporation was performed according to Dower *et al.* (1988).

Electrocompetent cells were prepared as follows: A single clone of *E. coli* was incubated in 20 ml LB medium overnight at 37 °C with moderate shaking. A volume of 500 ml LB medium was inoculated with 5 ml of this overnight culture and cultivated at 37 °C for 2 – 5 hours until an OD$_{600}$ of 0.6 – 0.8 was reached. The cells were incubated on ice for 30 min and harvested (4 °C, 5000 x g, 15 min). The cells were washed in sequence with 500 ml and 250 ml cold sterile de-ionized water and followed once with sterile 10 % (v/v) glycerol. The pelleted cells were resuspended in 2 ml sterile 10 % (v/v) glycerol, dispensed in 50 µl aliquots and frozen in liquid nitrogen immediately. The competent cells were stored at -80 °C for several months.

For electroporation the cells were thawed on ice. 0.1 - 1 µg desalted DNA to be transformed was added to 50 µl competent cells, mixed well and transferred to a precooled electroporation cuvette (*E. coli* Pulser cuvette, 0.2 cm gap; BioRad, Munich, Germany). Electroporation was carried out at 2.5 kV, 200 Ω and 25 µF with an *E. coli* Pulser (BioRad, Munich, Germany). 1 ml of LB medium was added, the cells were incubated at 37 °C for 1 hour with moderate shaking and then plated on LB plates containing 200 µg/ml ampicillin.
2.3.2 Electrotransformation in *M. smegmatis*

Competent *M. smegmatis* cells were prepared as described for *E. coli*. The bacteria were transfected by electroporation (Stover *et al.*, 1991) and selection was carried out on 7H10 plates containing 50 µg/ml kanamycin (see 2.3.1).

2.3.3 Preparation of plasmid DNA

Plasmid preparations were performed with the QIAprep Spin Miniprep Kit or the HiSpeed Plasmid Midi Kit (Qiagen, Hilden, Germany) according to the manufacturers advice.

2.3.4 Purification of genomic DNA from mycobacteria

Mycobacterial cells were disrupted in a Mikro-Dismembranator S (Braun, Melsungen, Germany) with 100 µl glass beads (150 – 212 microns; Sigma-Aldrich, Taufenkirchen, Germany). The glass beads were removed and the cell suspension homogenized with a QIAshredder (Qiagen, Hilden, Germany). Isolation of genomic DNA was done with the Dneasy Tissue Kit (Qiagen, Hilden, Germany) according to the manual.

2.3.5 Enzymatic DNA restriction

Restriction endo-nucleases were purchased from MBI Fermentas (St. Leon-Rot, Germany). In each restriction reaction an amount of 3 units enzyme per 1 µg DNA was used. Manufacturer recommended buffer, incubation temperature and time were used.
2.3.6 Ligation

For ligation the molar ratio of insert to plasmid was approximately 3:1. The reaction was carried out in a total volume of 20 µl T4 DNA ligase buffer containing 1 unit T4 DNA ligase (Roche, Mannheim, Germany) per 1 µg DNA. The reaction mixture was incubated at 16 °C overnight.

2.3.7 Agarose gel electrophoresis of DNA

The separation of DNA by analytical or preparative means was performed at 80 – 100 V in a Wide Mini-Sub Cell or DNA Sub Cell (BioRad, Munich, Germany). 1x TBE buffer (Table 2.5) was used as the gel and running buffer. The GeneRuler 1 kb DNA ladder (MBI Fermentas, St. Leon-Rot, Germany) served as the molecular size marker and 6x Loading Dye Solution (MBI Fermentas, St. Leon-Rot, Germany) as loading buffer. The agarose gels were stained with SYBR Gold solution (1:10000 in TBE; Molecular Probes, Leiden, Netherlands) for 30 min and analyzed with an UV Transilluminator (E.A.S.Y. RH-3 System; Herolab, Wiesloch, Germany).

Table 2.5: Composition of 1x TBE buffer

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>89 mM</td>
<td>Tris-base</td>
</tr>
<tr>
<td>89 mM</td>
<td>boric acid</td>
</tr>
<tr>
<td>2 mM</td>
<td>EDTA</td>
</tr>
</tbody>
</table>

2.3.8 DNA extraction from agarose gels

After separation on agarose gels (see 2.3.7) DNA fragments, obtained from PCR, were cut out of the gel and extracted with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturers advice.
2.3.9 Ethanol precipitation of DNA

1/10 vol 3 M sodium acetate at pH 4.8 and 2 vol ethanol (p.a.) were added to the DNA solution. The mixture was incubated on ice for 10 min and afterwards DNA was precipitated by centrifugation (20000 x g). The DNA pellet was washed twice with 70 % (v/v) ethanol, dried and resuspended in buffer or de-ionized H₂O.

2.3.10 Quantification of DNA

2.3.10.1 Absorbance measurement

The concentration dependent absorbance of nucleotides at 260 nm can be used to determine the concentration and purity of DNA solutions. Absorbance of the DNA solution was measured at 260 nm and 280 nm. An OD₂₆₀ of 1 corresponds to a double stranded DNA concentration of 50 µg/ml. A well purified DNA solution should have an OD₂₆₀/OD₂₈₀ ratio of 1.5 – 2.

2.3.10.2 Quantification of nucleic acids in agarose gels

Alternatively to the method described in 2.3.10.1, the concentration of nucleic acids can be determined in agarose gels (see 2.3.7). Thus, a defined amount of DNA Mass Ladder (Gibco, Karlsruhe, Germany) was used as a concentration standard.

2.3.11 Oligonucleotides

Desalted and lyophilized oligonucleotides were custom synthesized by Metabion (Martinsried, Germany). The primers used in this study are listed in Table 2.6.
Table 2.6: Primers used in this study

<table>
<thead>
<tr>
<th>synonym</th>
<th>sequence 5’ → 3’ (bold letters indicate the restriction site)</th>
<th>restriction site</th>
</tr>
</thead>
<tbody>
<tr>
<td>MtMycRFor</td>
<td>NNN NNN CTG CAG ATG GAA ACG TAC GAC ATC GCG ATC</td>
<td>PstI</td>
</tr>
<tr>
<td>MtMycRH6Rv</td>
<td>NNN NNN AAG CTT TCA GTG ATG ATG ATG ATG ACG CAG GCC AAG CAG GCC GTT</td>
<td>HindIII</td>
</tr>
<tr>
<td>MtRv2466cFor</td>
<td>CCC CCC CAT ATG CTC GAG AAG GCC CCC CAG</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtRv2466cH6Rv</td>
<td>CCC CCC GAA TTC CTA GTG ATG ATG ATG ATG ATG GTC GAA CTG AGG CCG CTC GGT</td>
<td>EcoRI</td>
</tr>
<tr>
<td>MtAhpCFor</td>
<td>G GCG CGC CAT ATG CCA CTG CTA ACC ATT GGC GA</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtAhpCH6Rv</td>
<td>CCG GCG GGA TCC TTA GTG ATG ATG ATG ATG GGCC CGA AGC CTT GAG GAG TT</td>
<td>BarnHI</td>
</tr>
<tr>
<td>MtTrxAFor</td>
<td>CCC CCC CAT ATG TGT ACC ACT CGA GAC CTC ACG</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtTrxAH6Rv</td>
<td>CCC CCC GAA TTC CTA GTG ATG ATG ATG ATG ATG GGA TGA AGT CTT TGT TGC ACG GCC</td>
<td>EcoRI</td>
</tr>
<tr>
<td>MtTrxBFor</td>
<td>CCC CCC CAT ATG GTG ACT ACC CGA GAC CTC ACT GCC</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtTrxBH6Rv</td>
<td>CCC CCC GAA TTC CTA GTG ATG ATG ATG ATG ATG GGC TGG TGC TCG CCC GTC</td>
<td>EcoRI</td>
</tr>
<tr>
<td>MtH6TrxCFor</td>
<td>CC CCC CCC CAT ATG CAT CAC CAT CAC CAT ACC GAT TCC GAG AAG TCC GCC</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtTrxCrV</td>
<td>CC CCC CCC AAG CTT CTA GGG GTG GGG AAG CAC GTC</td>
<td>HindIII</td>
</tr>
<tr>
<td>MtAhpDFor</td>
<td>CC CCC CCC CAT ATG AGT ATA GAA AAG CTC AAG GCC GCG</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtAhpDRv</td>
<td>CC CCC CCC AAG CTT TTA GCT TGG GCT TAG TGC CTC GAT</td>
<td>HindIII</td>
</tr>
<tr>
<td>MtH6TPxFor</td>
<td>CCC CCC CAT ATG CAT CAC CAT CAC CAT CAC GCA CAG ATA ACC CTC CGA GGA</td>
<td>Ndel</td>
</tr>
<tr>
<td>MtTPxRv</td>
<td>CCC CCC AAG CTT CTA GGC GCC CAG CGC GGC</td>
<td>HindIII</td>
</tr>
</tbody>
</table>

2.3.12 Polymerase chain reaction (PCR)

The PCR was performed in a total volume of 50 µl with the PCR Master Mix (ABgene, Hamburg, Germany). The composition of the PCR reaction is listed in Table 2.7.
Table 2.7: PCR reaction composition

<table>
<thead>
<tr>
<th>Component</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>chromosomal DNA / plasmid DNA</td>
<td>0.5 – 1 µg / 10 – 500 ng</td>
</tr>
<tr>
<td>5'-primer, 3'-primer</td>
<td>0.5 µM of each</td>
</tr>
<tr>
<td>Thermoprobe Plus DNA Polymerase</td>
<td>1.25 units</td>
</tr>
<tr>
<td>Tris-HCl (pH 8.8)</td>
<td>75 mM</td>
</tr>
<tr>
<td>(NH₄)₂SO₄</td>
<td>20 mM</td>
</tr>
<tr>
<td>Tween 20</td>
<td>0.01 % (v/v)</td>
</tr>
<tr>
<td>dATP, dCTP, dGTP, dTTP</td>
<td>200 µM of each</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>1.5 mM</td>
</tr>
<tr>
<td>sterile de-ionized water</td>
<td>to 50 µl total volume</td>
</tr>
</tbody>
</table>

The PCR reaction was carried out in a T3 Thermocycler (Biometra, Göttingen, Germany) as follows:

<table>
<thead>
<tr>
<th>Step</th>
<th>Time/Temperature</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denaturation</td>
<td>2 min 96 °C</td>
<td>1 cycle</td>
</tr>
<tr>
<td>Denaturation</td>
<td>1 min 96 °C</td>
<td></td>
</tr>
<tr>
<td>Annealing</td>
<td>1 min Tₐ</td>
<td></td>
</tr>
<tr>
<td>Elongation</td>
<td>3 min 72 °C</td>
<td>30 cycles</td>
</tr>
<tr>
<td>Elongation</td>
<td>10 min 72 °C</td>
<td>1 cycle</td>
</tr>
</tbody>
</table>

2.3.13 DNA sequencing

Automated non-radioactive sequencing of DNA was carried out according to the di-deoxy-method of Sanger (Sanger et al., 1977). The ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Darmstadt, Germany) was used on a 373A Applied Biosystems DNA Sequencing System (Applied Biosystems, Darmstadt, Germany) according to the manufacturers’ advice.
2.4 Biochemical methods

2.4.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE)

SDS polyacrylamide gels were used for determining the molecular weight of the denatured proteins and to check the efficiency of recombinant protein expression and purification. SDS-PAGE was performed with the Minigel System (dimension of the gel: 11 cm x 7 cm x 0.1 cm; Biometra, Göttingen, Germany) as described by Laemmli (1970). All samples were diluted 1:2 with 2-fold loading buffer (Table 2.8) and denatured at 95 °C for 10 min. Electrophoresis was performed at 60 V for the stacking gel and at 140 V for the running gel.

Table 2.8: Solutions used for SDS-PAGE

<table>
<thead>
<tr>
<th>2x SDS loading buffer</th>
<th>SDS electrophoresis buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mM Tris-HCl pH 6.8</td>
<td>25 mM Tris-base</td>
</tr>
<tr>
<td>200 mM DTT</td>
<td>250 mM glycine</td>
</tr>
<tr>
<td>4 % (w/v) SDS</td>
<td>0.1 % (w/v) SDS</td>
</tr>
<tr>
<td>0.2 % (w/v) bromophenolblue</td>
<td></td>
</tr>
<tr>
<td><strong>4x Upper Tris</strong></td>
<td><strong>4 x Lower Tris</strong></td>
</tr>
<tr>
<td>0.5 M Tris-HCl pH 6.8</td>
<td>1.5 M Tris-HCl pH 8.8</td>
</tr>
<tr>
<td>0.4 % (w/v) SDS</td>
<td>0.4 % (w/v) SDS</td>
</tr>
<tr>
<td><strong>stacking gel (4 %)</strong></td>
<td><strong>running gel (15 %)</strong></td>
</tr>
<tr>
<td>0.7 ml Rotiphorese Gel 30 (Roth, Karlsruhe, Germany)</td>
<td>7.5 ml Rotiphorese Gel 30 (Roth, Karlsruhe, Germany)</td>
</tr>
<tr>
<td>1.25 ml Upper Tris</td>
<td>3.8 ml Lower Tris</td>
</tr>
<tr>
<td>3 ml de-ionized H₂O</td>
<td>3.6 ml de-ionized H₂O</td>
</tr>
<tr>
<td>12 µl TEMED</td>
<td>18 µl TEMED</td>
</tr>
<tr>
<td>6 µl 40 % (w/v) APS</td>
<td>12 µl 40 % (w/v) APS</td>
</tr>
</tbody>
</table>
2.4.2 Coomassie staining

SDS-PAGE gels were fixed for 30 min in a fixing solution (40 % (v/v) ethanol, 10 % (v/v) acetic acid and 50 % (v/v) de-ionized H₂O). The Coomassie staining solution (2 tablets PhastGel Blue R (Amersham Biosciences, Freiburg, Germany) in 1 liter fixing solution) was prewarmed to 55 °C – 60 °C, and the gels were stained for 30 min. After staining the gels were de-stained with a mixture of 25 % (v/v) ethanol, 8 % (v/v) acetic acid and 67 % (v/v) de-ionized H₂O, using a de-stainer model 556 (BioRad, Munich, Germany).

2.4.3 Determination of protein concentration

Protein concentrations were determined by the method of Bradford (1976) using the BioRad Protein Assay (BioRad, Munich, Germany) and BSA (Bovine Serum Albumin) as a standard, according to the manufacturers advice.

2.4.4 Ultra-filtration

Ultra-filtration is a convective process that uses anisotropic semi-permeable membranes to separate macromolecular species and solvents primarily on the basis of their size. It is particularly appropriate for the concentration of macromolecules and has also been used for solvent exchange. For ultra-filtration the Vivaspin centrifugal concentrators (Sartorius, Göttingen, Germany) were used. The molecular weight cut off was chosen to correspond to the molecular weight of the protein.
2.4.5 N-terminal amino acid sequencing

The protein of interest was separated by SDS-PAGE (see 2.4.1), blotted onto PVDF membrane (Immobilon P; Millipore, Schwalbach, Germany) for 30 min at 15 V using a Trans-Blot Semi-Dry Transfer Cell (BioRad, Munich, Germany). The membrane was stained with Coomassie solution (see 2.4.2) until the bands could be seen. The band of interest was cut out of the membrane, washed in de-ionized H$_2$O and used for sequencing. The N-terminal amino acid sequencing was kindly performed on a protein sequencer 473A (Applied Biosystems, Darmstadt, Germany) by Rita Getzlaff (GBF, Braunschweig, Germany).

2.4.6 Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry

The molecular masses of the purified recombinant proteins were analyzed by MALDI-TOF mass spectrometry at the GBF (Braunschweig, Germany) using a Bruker Reflex MALDI-TOF (Bruker, Bremen, Germany).

2.4.7 Isolation of mycothiol

Mycothiol (MSH) was isolated from Mycobacterium smegmatis. *M. smegmatis* cells were disrupted by boiling them for 10 min at 95 °C in 10 mM Tris-HCl at pH 8. MSH was isolated from the crude *M. smegmatis* soluble extract essentially as described by Unson *et al.* (1998).
2.5 Expression and purification of recombinant proteins

2.5.1 Creation of a Master Seed Bank

To standardize organism cultures and expression conditions a Master Seed Bank (MSB) was set up for each expression strain. Bacterial stocks were prepared from a single colony of each expression strain and stored at -80 °C in LB (E. coli) or 7H9 (M. smegmatis) broth containing 50 % (v/v) glycerol.

2.5.2 Induced expression of recombinant proteins in E. coli

The open reading frames (ORF) of the genes of interest were cloned into the pET22b(+) expression vector (Novagen, Madison, USA) under the control of an IPTG inducible bacteriophage T7 RNA polymerase promoter. 100 ml preculture (LB + 200 µg/ml ampicillin + 1 % (w/v) glucose) was inoculated with 1 vial from the MSB and incubated overnight at 37 °C with moderate shaking. The main culture was inoculated with an OD$_{600}$ of 0.1 and grown at 37 °C until an OD$_{600}$ of 0.6 to 0.8 was reached. At that point expression was induced with 0.5 mM IPTG and the incubation temperature was changed to 30 °C. The LB medium was supplemented with glucose to maintain low basal expression levels (Grossman et al., 1998). After up to overnight expression, cells were harvested by centrifugation (5000 x g, 15 min, 4 °C) and cell pellets were stored at -20 °C until they were used for purification. Cell cultivation and expression was either performed in Erlenmeyer flasks or in a 5-liter Biostat B Fermentor (B. Braun, Melsungen, Germany). All recombinants overexpressed proteins, the corresponding E. coli strain and induction times are listed in Table 2.9.
### Table 2.9: Overexpressed, recombinant proteins

<table>
<thead>
<tr>
<th>rec. protein</th>
<th>6xHis-tag</th>
<th>plasmid</th>
<th>strain</th>
<th>induction time</th>
</tr>
</thead>
<tbody>
<tr>
<td>MtRv2466c</td>
<td>C-terminal</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>4 h</td>
</tr>
<tr>
<td>MtAhpC</td>
<td>C-terminal</td>
<td>pET22b(+)</td>
<td>E. coli BL21 (DE3)</td>
<td>overnight</td>
</tr>
<tr>
<td>MtAhpD</td>
<td>non</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>4 h</td>
</tr>
<tr>
<td>MtTrxA</td>
<td>C-terminal</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>5 h</td>
</tr>
<tr>
<td>MtTrxB</td>
<td>C-terminal</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>5 h</td>
</tr>
<tr>
<td>MtTrxC</td>
<td>N-terminal</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>5 h</td>
</tr>
<tr>
<td>MtTR</td>
<td>N-terminal</td>
<td>pTrcHis A</td>
<td>E. coli Tuner (DE3)</td>
<td>5 h</td>
</tr>
<tr>
<td>MtTPx</td>
<td>N-terminal</td>
<td>pET22b(+)</td>
<td>E. coli Tuner (DE3)</td>
<td>5 h</td>
</tr>
</tbody>
</table>

#### 2.5.3 Induced expression of MtMycR in *M. smegmatis*

The MycR ORF was cloned with a C-terminal His-tag into the pMV261 vector under the control of the mycobacterial HSP60 promoter. 150 ml preculture (7H9 + 50 µg/ml kanamycin) of the recombinant *M. smegmatis* was inoculated with 1 vial from the MSB and incubated for 48 h at 37 °C with moderate shaking. The main culture was inoculated with an OD<sub>600</sub> of 0.4 and grown at 30 °C until an OD<sub>600</sub> of 1.0 was reached. At that point expression was induced by heat shock at 45 °C. At an OD<sub>600</sub> of 2 the cells were harvested by centrifugation (7000 x g, 30 min, 4 °C) and cell pellets were stored at -20 °C until they were used for purification. Cultivation and expression of the recombinant mycobacterial strain was performed in a 5-liter Biostat B Fermentor (B. Braun, Melsungen, Germany).
2.5.4 **Cell disruption by sonication**

The pelleted cells were re-supended in 1/10 of the suitable buffer for purification or other means. The cell suspension was cooled on ice and sonicated for 1 min with a Sonopuls Ultrasonic Homogenizer HD 2200 (Bandelin, Berlin, Germany). For volumes more than 10 ml the sonication step was repeated 3 times. After the cell disruption the crude extracts were centrifuged at 25000 x g, 4 °C for 30 min. The supernatant, containing the soluble proteins, was used for purification or for other purposes.

2.5.5 **Chromatographic methods**

The BioLogic Workstation or the BioLogic DuoFlow System (BioRad, Munich, Germany) was used for all chromatographic applications.

2.5.5.1 **Nickel chelate chromatography**

For the purification of 6xHis-tagged recombinant proteins the Ni-NTA Superflow resin (Qiagen, Hilden, Germany) was used. This resin allows one-step purification of 6xHis-tagged proteins using high flow rates and pressures for efficient FPLC applications. The capacity for 6xHis-tagged proteins is 5 – 10 mg/ml. Purification buffers and methods were carried out essentially according to the QIAexpressionist Handbook (5th edition; Qiagen, Hilden, Germany). Cells were sonicated in 50 mM NaH$_2$PO$_4$, 300 mM NaCl, 10 mM imidazole at pH 8 (binding buffer) and the soluble extract was applied to the column. The column was washed with 5-bed volumes of binding buffer and finally eluted with a linear gradient from 0 % to 100 % elution buffer (binding buffer with 500 mM imidazole). The imidazole concentrations at which the different heterologously expressed proteins eluted, are listed in Table 2.10.
Table 2.10: Imidazole concentration for elution of the recombinant proteins

<table>
<thead>
<tr>
<th>recombinant protein</th>
<th>imidazole concentration for elution</th>
</tr>
</thead>
<tbody>
<tr>
<td>MtRv2466c</td>
<td>120 mM</td>
</tr>
<tr>
<td>MtMycR</td>
<td>100 mM</td>
</tr>
<tr>
<td>MtAhpC</td>
<td>190 mM</td>
</tr>
<tr>
<td>MtTrxA</td>
<td>150 mM</td>
</tr>
<tr>
<td>MtTrxB</td>
<td>125 mM</td>
</tr>
<tr>
<td>MtTrxC</td>
<td>100 mM</td>
</tr>
<tr>
<td>MtTR</td>
<td>110 mM</td>
</tr>
<tr>
<td>MtTPx</td>
<td>180 mM</td>
</tr>
</tbody>
</table>

2.5.5.2 Anion exchange chromatography

An UNOsphere Q column (BioRad, Munich, Germany) was used for anion exchange chromatography according to the manufacturer's instruction manual. UNOsphere Q is an high-capacity, high-throughput anion exchange capture support, based on acrylamide and vinylic monomers, designed for process chromatography. The column was equilibrated with 10 bed volumes 20 mM Tris-HCl at pH 7.4. The sample was loaded onto the column, which was then washed with 5 bed volumes of the equilibration buffer. The proteins were eluted by a linear gradient of 0 % to 100 % 20 mM Tris-HCl, 1 M NaCl at pH 7.4.

2.5.5.3 Hydrophobic interaction chromatography (HIC)

For hydrophobic interaction chromatography, a HiLoad 16/10 Phenyl Sepharose High Performance column (Amersham Biosciences, Freiburg, Ger-
many) was used according to the manufacturers advice. HIC separates proteins and peptides on the basis of their varying strength of interaction with hydrophobic groups attached to an uncharged gel matrix. The column was equilibrated with 20 mM Tris-HCl, 1 M (NH₄)₂SO₄ at pH 7.4. The protein solution was diluted with 20 mM Tris-HCl, 2 M (NH₄)₂SO₄ at pH 7.4 till the final concentration of (NH₄)₂SO₄ reached 1 M. The sample was loaded onto the column, which was then washed with 5 bed volumes of the equilibration buffer. The elution was performed by linearly decreasing the concentration of (NH₄)₂SO₄. The recombinant expressed mycobacterial AhpD eluted at 400 mM (NH₄)₂SO₄.

2.5.5.4 Gel permeation

Sephadex G-25 (Amersham Biosciences, Freiburg, Germany) was used for desalting and for the buffer exchange of larger volumes of protein solutions. Sephadex is a bead-formed gel. Gel filtration separates molecules according to their relative sizes. Large molecules are totally excluded while smaller sized molecules enter the beads to varying extents according to their sizes. Large molecules thus leave the column first followed by smaller molecules in the order of their decreasing size.

2.5.6 Estimation of the molecular size of native proteins

Reduced MtAhpC was chromatographed on a Superdex 200 HR 10/30 column (Pharmacia, Freiburg, Germany) using a mixture of 10 mM sodium phosphate buffer and 20 mM DTT at pH 7.6 as the eluent. High molecular weight standards (Pharmacia, Freiburg, Germany) were used for column calibration. Eluted peroxidase was identified by activity measurements and SDS-PAGE. For size determination of oxidized MtAhpC, the enzyme was incubated with 300 µM t-bOOH at room temperature for 30 min in 10 mM
sodium phosphate buffer at pH 7.6. The molecular weight was then estimated by gel permeation chromatography as described above. Gel permeation analyses of reduced and oxidized MTAhpD and MTPx were performed essentially as described for MTAhpC, using a Superdex 75 HR 10/30 column (Pharmacia, Freiburg, Germany) and low molecular weight standards (Pharmacia, Freiburg, Germany) for column calibration.

2.6 Electron microscopy studies

The electron microscopy studies were kindly facilitated by Heinrich Lünsdorf and Elke Barth (GBF, Braunschweig, Germany). After gel permeation the reduced or oxidized MTAhpC (60 µg/ml final concentration) was adsorbed to an ultrathin carbon foil for 30 s at ambient temperature and was negatively stained immediately in 4 % (w/v) uranyl acetate at pH 4.5, according to Valentine et al. (1968). The carbon foil was picked up with perforated collodion microgrids, prepared according to Lünsdorf and Spiess (1986), blotted with filter paper and air-dried. Samples were analyzed with an energy-filtered transmission electron microscope (EFTEM) CEM 902 (Zeiss, Oberkochen, Germany) in the elastic bright-field imaging mode (spectrometer slit: 30 eV; objective aperture: 30 µm; condenser aperture: 300 µm) at 85,000 primary magnification close to the Scherzer focus. Images were directly registered with a cooled 1024 x 1024 CCD-camera (Proscan, Scheuring, Germany) and digitally optimized for sharpness and contrast with Corel Photopaint computer software (Corel Corporation, Ottawa, Canada).
2.7 Enzymatic assays

2.7.1 Insulin reduction assay

Interaction of thioredoxin-like proteins with thioredoxin reductase (TR) was tested through the insulin reduction assay as described by Luthman and Holmgren (1982). In the insulin reduction assay, the rate of conversion of NADPH to NADP⁺ is measured by the decrease in $A_{340}$. In this process, reduction equivalents are transferred from NADPH to thioredoxin (Trx) via TR. The reduced form of Trx in turn reduces insulin, thereby separating the A and B chains. The test system contained 13.5 µM $Mt$TR, variable concentrations of Trx-like proteins ($Mt$TrxA, $Mt$TrxB, $Mt$TrxC, $Mt$AhpD or Rv2466c; 0.7 µM to 10 µM), 200 µM bovine insulin (Sigma, Taufenkirchen, Germany), 400 µM NADPH in 50 mM HEPES, 2 mM EDTA at pH 7.4 in a total volume of 500 µl. The decrease in $A_{340}$ was monitored over time, and the amount of NADPH oxidized was calculated with a molar extinction coefficient of 6296 M⁻¹cm⁻¹.

2.7.2 MycR assay

The activity of $Mt$AhpC with MSH and $Mt$MycR was tested at 25 °C in a system that contained 450 µM NADH or NADPH, 0.2 µM – 20 µM $Mt$MycR, 0.2 µM – 20 µM MSH, 0.2 µM – 20 µM $Mt$AhpC, 73 µM $t$-bOOH in 50 mM HEPES, 1 mM EDTA at pH 7.4 in a final volume of 500 µl. The decrease in $A_{340}$ was monitored over time.

2.7.3 AhpD assay

The specific activity of $Mt$AhpC with $Mt$AhpD was quantified by measuring the initial velocities through monitoring the NADH oxidation at 340 nm at 25
°C. The test system contained 450 µM NADH, 200 nM *Mt*AhpD, 0.4 U bovine lipoamide dehydrogenase (Sigma, Taufenkirchen, Germany), 50 µM lipoamide, 0.5 µM – 10 µM *Mt*AhpC, 73 µM t-bOOH in 50 mM HEPES, 1 mM EDTA at pH 7.4 in a final volume of 500 µl. The reaction was preincubated for 15 min at 25 °C and started by the addition of peroxide. For the AhpD-dependent kinetic studies of *Mt*AhpC, the conditions were nearly the same as for the measurement of the activity using 5 µM *Mt*AhpC and fixed *Mt*AhpD concentrations. A range between 5 µM – 65 µM t-bOOH was used for the calculation of the kinetic pattern.

2.7.4 AhpC and TPx assay

The specific activities of *Mt*AhpC with *Mt*TrxC and *Mt*TPx with *Mt*TrxB or *Mt*TrxC were obtained by measuring initial velocities monitoring the NADPH oxidation at 340 nm at 25 °C. The test system contained 450 µM NADPH, 10 µM *Mt*TR, 10 µM *Mt*TrxB or *Mt*TrxC, 0.5 µM – 15 µM *Mt*AhpC or 0.2 µM – 5 µM *Mt*TPx, 100 nM bovine catalase (Roche, Mannheim, Germany), 73 µM t-bOOH in 50 mM HEPES, 1 mM EDTA at pH 7.4 in a final volume of 500 µl. The reaction was preincubated for 15 min at 25 °C and started by the addition of peroxide. For the kinetic studies of *Mt*AhpC and *Mt*TPx the conditions were nearly the same as for the measurement of the activities using 5 µM of the peroxidase and fixed thioredoxin concentrations. A range between 5 µM – 65 µM t-bOOH was used for the calculation of the kinetic pattern. Specificity for H₂O₂, cumene hydroperoxide, linoleic acid hydroperoxide and phosphatidylcholine hydroperoxide were investigated accordingly. The last two were prepared from soybean lipoxygenase-catalyzed oxidation of the corresponding lipids and were kindly provided by R. Brigelius-Flohé (German Institute of Human Nutrition, Potsdam, Germany).
2.7.5 Steady-state kinetics

Substrate turnover by peroxidases was monitored continuously by NAD(P)H consumption in a coupled test system. The data was analyzed according to Dalziel (1957). Results are presented in terms of the general Dalziel-equation for two substrate reactions:

\[
\frac{[E_0]}{v} = \Phi_0 + \frac{\Phi_1}{[A]} + \frac{\Phi_2}{[B]} + \frac{\Phi_{1,2}}{[A][B]}
\]  

(1)

Where, \([E_0]\) is the total enzyme concentration, \(v\) is the initial velocity at pertinent substrate concentrations, and \(\phi_0, \phi_1, \phi_2, \) and \(\phi_{1,2}\) are kinetic coefficients characterizing a particular enzyme. With enzyme mechanisms not involving ternary complexes between the enzyme and both substrates, the term \(\phi_{1,2}/[A][B]\) is zero. In such “ping-pong” or enzyme substitution mechanisms the rate equation simplified to

\[
\frac{[E_0]}{v} = \Phi_0 + \frac{\Phi_1}{[A]} + \frac{\Phi_2}{[B]}
\]  

(2)

Accordingly, re-plotting of the ordinate intercepts, i.e., the reciprocal enzyme-normalized apparent maximum velocities for infinite concentrations of \(t\)-bOOH (= [A]) against the reciprocal concentrations of the corresponding reductant (= [B]) yields \(\phi_0\) as ordinate intercepts and \(\phi_2\) being the slope. \(\phi_0\) is defined as the reciprocal value of the velocity at infinite concentration of both substrates, that means of \(k_{\text{cat}}\). The reciprocal net forward rate constant \(k'_{1}\), which describes the oxidation of reduced enzyme by ROOH, by definition, equals \(\phi_1\). \(\phi_2\) describes a reductant-dependent step, thus must be the reciprocal \(k'_{2}\).
2.7.6 Stopped-flow kinetics

The stopped-flow analyses were kindly performed by Rafael Radi and Madia Trujillo (Departamento de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay).

2.7.6.1 Direct measurement of peroxynitrite reduction by MtTPx by stopped-flow technique

MtTPx was reduced by overnight treatment with 10 mM DTT at 4 °C. Excess reductant was removed immediately before use by gel filtration on Hitrap columns (Amersham Biosciences) using degased 100 mM sodium phosphate buffer, 0.1 mM DPTA (diethylene-triamine-pentaacetic acid) at pH 7 as the eluent, followed by extensive bubbling with argon. Peroxynitrite was synthesized in a quenched flow reactor as described previously (Radi et al., 1991; Beckman et al., 1994), and excess hydrogen peroxide was removed by treatment with MnO₂. Peroxynitrite concentration was determined spectrophotometrically by the measurement of its absorption at 302 nm in 1 M NaOH (ε_{302} = 1670 M⁻¹cm⁻¹). The kinetics of peroxynitrite reaction with reduced MtTPx was studied at 302 nm in a stopped-flow spectrophotometer (SX-17MV, Applied Photophysics) with a mixing time of less than 2 ms, following peroxynitrite decomposition in the presence and absence of the enzyme. To ensure the accuracy of the rate constant determinations, 200 absorbance measurement points were acquired during the initial part of the reaction (first 50 ms) and 200 additional points were acquired until more than 90 % of the peroxynitrite had decomposed (0.5 ms – 20 ms). Computer assisted simulations were performed using Gepasi software (Mendes, 1997). With this experimental approach peroxynitrite can either react with the reduced enzyme to yield the oxidized enzyme and nitrite or it can de-
compose to nitrate after a proton-catalyzed isomerization ($k = 0.26 \text{ s}^{-1}$ at pH 7.4 and 25 °C; Koppenol et al., 1992).

$$\text{ONO}_2\text{H} \rightarrow \text{NO}_3^- + \text{H}^+ \quad (3)$$

$$\text{ONO}_2\text{H} + \text{MtTPx}_{\text{red}} \rightarrow \text{NO}_2^- + \text{MtTPx}_{\text{ox}} \quad (4)$$

The apparent second order rate constant for the reaction of the enzyme and peroxynitrite at pH 7.4 and 37 °C was varied in order to get the best fit to experimental data.

### 2.7.6.2 Rate constant determination of peroxynitrite reduction by competition experiments

Mn$^{3+}$ porphyrins are rapidly oxidized by peroxynitrite ($k = 10^5 - 10^7 \text{ M}^{-1}\text{s}^{-1}$ at pH 7.4 and 37 °C) to O=Mn$^{4+}$ which can be conveniently monitored at the Soret band (Ferrer-Sueta et al., 2003). The inhibitory effect of MtTPx on the oxidation of Mn$^{3+}$-meso-tetrakis[(N-ethyl)pyridinium-2-yl]porphyrin (Mn$^{3+}$-TE-2-PyP) by peroxynitrite was determined by stopped-flow techniques, since Mn$^{4+}$ is an unstable species that is readily reduced back to Mn$^{3+}$, presumably by nitrite (Ferrer-Sueta et al., 1999). Mn$^{3+}$-TE-2-PyP oxidation by peroxynitrite was monitored at different MtTPx concentrations. Experiments were performed at 25 °C and the pH was measured at the outlet.

Percentage inhibition of peroxynitrite-dependent Mn$^{3+}$-TE-2-PyP oxidation by MtTPx can be fitted to a hyperbolic function of the type $y = ax/(b+x)$, where “$a$” corresponds to the percentage of initial Mn$^{3+}$-porphyrin oxidation by peroxynitrite (in the absence of competing enzyme) and “$b$” corresponds to the concentration of enzyme that half-inhibits peroxynitrite-dependent Mn$^{3+}$-porphyrin oxidation. From this plot a “$b$” value of 5.7 µM was obtained. At that point $k_{\text{MtTPx}}[\text{MtTPx}]$ equals $k_{\text{Mn}^{3+}}[\text{Mn}^{3+}]$, which allows the calculation of $k_1$ for the reaction of the peroxidase with peroxynitrite ($k_{\text{MtTPx}}$).
2.8 Molecular modeling

The molecular modeling was kindly done by Birgit Hofmann (GBF, Braunschweig, Germany). Structure models of \textit{MtTPx} were generated using Bragi (Schomburg and Reichelt, 1988) and sequence alignments of Clustalx (Thompson \textit{et al.}, 1997). The model of the \textit{MtTPx} was based on the structure of \textit{Crithidia fasciculata} tryparedoxin peroxidase (TXNPx) (Hofmann \textit{et al.}, 2001) and other peroxiredoxins (Hirotsu \textit{et al.}, 1999; Schroeder \textit{et al.}, 2000). The model of the TPx/Trx intermediate was generated from the model of oxidized \textit{C. fasciculata} TXNPx (Hofmann \textit{et al.}, 2001) and the structure of \textit{E. coli} Trx using O (Jones \textit{et al.}, 1991). Initially, the model of oxidized \textit{MtTPx} alone was refined (Amber6, University of California at San Francisco, www.amber.ucsf.edu/amber/indexes.html) by energy minimization to release strain introduced by sequence exchange. The protein complex was constructed from those refined \textit{MtTPx} coordinates. Those of \textit{MtTrxC} were restrained by the introduction of a disulfide bond between C34 of \textit{MtTrxC} and C93 of \textit{MtTPx}, and refined by energy minimization, a 50 ps molecular dynamics simulation and a final energy minimization. Calculations were carried out using an 8 Å water shell around the protein molecules.

2.9 Computer analyses

For DNA sequence analysis, alignments, primer design and primer analysis the Vector NTI 6.0 program (InforMax Inc., Oxford, UK) was used. Micrografx Designer 4.1 (Corel Corporation, Ottawa, Canada) was used for creation of figures and schemes. Kinetics data were analyzed by Sigma Plot 8.0 (SPSS Inc., Chicago, USA). Database searches were performed using the NCBI (http://www.ncbi.nlm.nih.gov) and TubercuList (http://genolist.pasteur.fr/TubercuList) databases.
3 Results

3.1 Preparation of system components

The *M. tuberculosis* genome (Cole et al., 1998) was screened for homologues of AhpF, thioredoxin-related proteins and peroxiredoxins. For the reconstitution of different peroxidase systems the components were prepared as follows:

The *Mt*MycR ORF (Rv2855) was amplified from *M. tuberculosis* genomic DNA by PCR with the primers *Mt*MycRFor and *Mt*MycR6Rv. The PCR product was cloned into the mycobacterial expression vector pMV261, digested with corresponding set of restriction enzymes. Protein expression was induced in *M. smegmatis* by heat shock (45 °C) and the soluble protein was purified by nickel chelate chromatography.

The AhpD ORF (Rv2429) was amplified by PCR using the primers *Mt*AhpDFor and *Mt*AhpDRv and cloned into the procaryotic expression vector pET22b(+) digested with corresponding set of enzymes. Expression was induced in *E. coli* Tuner (DE3) with 0.5 mM IPTG at 30 °C. The heterologously expressed protein was primarily found in the soluble extract. *Mt*AhpD was purified to homogeneity by anion exchange chromatography and hydrophobic interaction chromatography.

The AhpC (Rv2428), TrxA (Rv1470), TrxB (Rv1471), TrxC (Rv3914), Rv2466c and TPx (Rv1932) ORFs were amplified by PCR using the corresponding primers listed in Table 2.6. The PCR products were cloned into pET22b(+) and expression was induced in *E. coli* Tuner (DE3) or BL21 (DE3) with 0.5 mM IPTG at 30 °C (induction times are listed in Table 2.9). All proteins were primarily found in the soluble extract. Purification to homo-
geneity of the His-tagged proteins (TrxA, TrxB, TrxC, AhpC, Rv2466c and TPx) was achieved by nickel chelate chromatography (for example see Fig. 3.1).

The correctness of the sequence was verified by DNA sequencing and the identities of the proteins were confirmed by MALDI-TOF analysis and N-terminal Edman degradation.

![Fig. 3.1: Purification of MtTrxA, B and C using nickel chelate chromatography. SDS-PAGE followed by Coomassie blue staining. Lane 1, crude extract of recombinant E. coli Tuner (DE3) [pET22b(+) MtTrxA] 4 hours after induction; lane 2, purified MtTrxA; lane 3, crude extract of recombinant E. coli Tuner (DE3) [pET22b(+) MtTrxB] 4 hours after induction; lane 4, purified MtTrxB; lane 5, crude extract of recombinant E. coli Tuner (DE3) [pET22b(+) MtTrxC] before induction (control); lane 6, purified MtTrxC; M, protein molecular weight markers. Molecular masses (in kilodaltons) are indicated to the left of the gel.]

3.2 Peroxide detoxification pathways

3.2.1 Attempt to reconstitute a mycothiol reductase system

Although attempts to substitute the missing AhpF by homologous mycothiol reductase (MtMycR) and mycothiol (MSH) for alkyl hydroperoxide reductase (MtAhpC) reduction have failed so far (Vergauwen et al., 2001), a reconstitution of that system was tried for verification. It was confirmed that MtMycR
does not reduce \textit{MtAhpC}. Neither did MSH even if kept in its thiol form by NAD(P)H and \textit{MtMycR} efficiently reduce \textit{MtAhpC} (see 2.7.2). The potential function of \textit{MtMycR} and MSH, a small molecular weight thiol proposed to substitute the missing glutathione in mycobacteria, remains elusive. The unsuccessful attempt to reduce \textit{MtAhpC} rules out its function as \textit{MtAhpC} reductant.

\subsection*{3.2.2 Reconstitution of the AhpD-dependent AhpC system}

It was also confirmed that \textit{MtAhpD} is reduced by lipoamide and can in turn reduce \textit{MtAhpC}, as described by Bryk \textit{et al.} (2002). Lipoamide, kept reduced by NADH and, for convenience, by bovine lipoamide reductase, together with \textit{MtAhpD} and \textit{MtAhpC} constitute a peroxidase system.

\subsection*{3.2.3 A novel thioredoxin-dependent AhpC system}

Intrigued by the recent observation that \textit{Helicobacter pylori}, which like \textit{M. tuberculosis} lacks AhpF, uses thioredoxin for AhpC reduction (Baker \textit{et al.}, 2001), attempt was made to reconstitute mycobacterial peroxidase systems by combining AhpC with thioredoxin reductase (\textit{MtTR}) and various CXXC-containing proteins (Fig. 3.2).
**Fig. 3.2:** Alignment of thioredoxin A, B and C and amino acid sequences of AhpD and Rv2466c from *M. tuberculosis*. Conserved residues are shown in red, **** indicate the CXXC motifs.

*MtTR*, which also is homologous to AhpF, did not reduce *Mt*AhpD. *MtTR* did neither reduce *Mt*TrxA nor the glutaredoxin-related Rv2466c protein but only the *Mt*TrxB and C, as was shown in the insulin reduction assay described by Holmgren and Luthman (1982). TrxB and C were shown to have similar activities, although the redox activity of TrxC was somewhat higher than TrxB (Fig. 3.3). Thus, *M. tuberculosis* has at least two functionally active thiore-
doxins that may protect the pathogen against oxidants derived from the macrophage.

Fig. 3.3: Results of the insulin reduction assay (see 2.7.1). MtTR was used in a concentration of 13.5 µM in combination with variable concentrations of MtTrxB or MtTrxC (0.7 to 4.6 µM) in a total volume of 500 µl. The decrease in A₃₄₀ was monitored over time, and the amount of oxidized NADPH was calculated with a molar extinction coefficient of 6296 M⁻¹cm⁻¹.

Surprisingly, MtTrxC efficiently reduced MtAhpC, while MtTrxB did not. Hillias et al. (2000) reported that thioredoxin and thioredoxin reductase are not the native partners for MtAhpC and MtAhpD. An explanation for the deviation from the results reported here could be that they did not use TrxC or they could not measure activity due to spontaneous NADPH consumption. When that peroxidase system was reconstituted, the system components led to an unspecific NADPH consumption without the addition of peroxide. H₂O₂ production by autoxidation of reduced MtTR was considered to cause that complication. Indeed there was no NADPH consumption observed after addition of catalase. In further experiments, based on the TR/Trx system, catalase was added to the test systems and the activity was measured with an organic hydroperoxide which is not a substrate of catalase.
3.2.4 Another novel thiol peroxidase system

*MtTrxC* also reduced another mycobacterial peroxiredoxin (Rv1932) that, by sequence homology, had been classified as a “thiol peroxidase” (TPx) but had never been investigated in regards to its activity and specificity. While studying proteome information on *M. tuberculosis* (Mollenkopf et al., 1999) we noticed that Rv1932 (TPx) was present as a dominant spot in 2-D gels. Homologues of TPx are distributed throughout most or all eubacterial species, both Gram-negative and Gram-positive, and are found in pathogenic strains such as *Helicobacter pylori* (Wan et al., 1997), but biochemical and genetic analyses have been limited primarily to *E. coli* TPx (*EcTPx*). In response to oxidative stress, *E. coli* up-regulates TPx expression (Cha et al., 1995; Kim et al., 1996; Kim et al., 1999), and *tpx* deletion mutants, while still viable, were more susceptible to oxidative stress and displayed diminished colony sizes and numbers after exposure to peroxide (Cha et al., 1996). *EcTPx* forms a Trx-linked peroxidase system capable of reducing H$_2$O$_2$ and ROOH and protecting against glutamine synthetase inactivation by a mixed function oxidation system (Cha et al., 1995; Baker and Poole, 2003).

*MtTPx* not only accepted *MtTrxC*, but also *MtTrxB* although with a slightly lower affinity and reactivity (Table 3.1). *MtTPx* belongs to a subfamily of 2-Cys-peroxiredoxins which, in contrast to AhpC and other 2-Cys-peroxiredoxins, are considered to be functionally monomeric. Their mechanism of action is believed to involve oxidation of an N-proximal cysteine residue, here Cys-60, to a sulfenic acid derivative by the hydroperoxide substrate. That is followed by formation of an intramolecular disulfide bridge with a distal cysteine, here Cys-94 (see Fig. 4.1). In comparison, in the oligomeric 2-Cys-peroxiredoxins the corresponding reaction center is built up between two subunits (Hofmann et al., 2002; Wood et al., 2003a; Baker and Poole, 2003).
3.3 kinetics and particularities

For the characterization and classification of the peroxidase systems discovered in this study, the different systems were analyzed by steady-state kinetics. The kinetic behaviour of the analyzed peroxiredoxins (MtAhpC and MtTPx) was only investigated with the most convenient substrate, t-butyl hydroperoxide. As an additional measure of precaution, sufficiently high enzyme concentration was chosen to allow completion of the reaction within less than 10 min. Initial velocities were read from the substrate consumption curves that correspond for up to 13 residual substrate concentrations giving equidistant abscissa points in the double reciprocal plot (primary plot). Thereby, a balanced and unbiased statistical weight of the individual velocities over the substrate range between 95 % and 3 % of the starting concentration was guaranteed. Three data sets were thus generated. The slopes of the regression lines and the ordinate intercepts of three to five independent experiments were averaged and used for the generation of secondary plots to obtain kinetic coefficients and constants (see 2.7.5).

3.3.1 The AhpD-dependent AhpC system

For comparison of the different enzyme systems discovered in this thesis, the MtAhpD/MtAhpC system was analyzed at steady-state kinetics, elucidated here for the first time. The time progression curves were unusual, starting with a lag phase when the fully reduced system was started with t-butyl hydroperoxide (t-bOOH) as MtAhpC substrate (Fig. 3.4, trace A; arrow). Reversible inhibition by the initially high hydroperoxide concentration does not account for the phenomenon, since it is observed identically from 20 µM up to 73 µM initial [t-bOOH]. Surprisingly, the reaction started at maximum rate if MtAhpC and MtAhpD were preincubated with t-bOOH for 2 min (Fig. 3.4, trace B) indicating a facilitated interaction of the reactant pairs.
**Fig. 3.4: Oxidative activation of the MtAhpC/MtAhpD system by t-bOOH.** *MtAhpC* activity with *MtAhpD* as cosubstrate was tested in a coupled test system where *MtAhpD* oxidation is continuously monitored by lipoamide/lipoamide dehydrogenase-mediated NADH consumption. Trace A: The reaction mixture was preincubated for 15 min at 25 °C under reductive conditions and started by the addition of t-bOOH (▼). Trace B: The reaction mixture except *MtAhpC*, *MtAhpD* and t-bOOH was preincubated for 15 min at 25 °C. *MtAhpC*, *MtAhpD* and the hydroperoxide were preincubated together for 2 min at 25 °C and the reaction was started by the addition of this mixture (▼). Notice the delayed onset of NADH consumption in trace A (arrow).

Redox-dependent conformational changes might improve the accessibility of the reaction centers or transfer the participating proteins into an activated form. Therefore the oligomerization states of *MtAhpD* and *MtAhpC* were analyzed.

The X-ray structure of AhpD shows that the protein builds up a trimer in a symmetrical cloverleaf arrangement. Each subunit exhibits a new all-helical protein fold in which the two catalytic sulfhydryl groups, Cys-130 and Cys-133, are located near a central cavity in the trimer (Nunn et al., 2002; Bryk et al., 2002). AhpC of *S. typhimurium* tends to form decamers depending on its redox status (Wood et al., 2002). For investigating the impact of the redox state on the oligomerization, the unmodified *MtAhpC* was reduced by DTT or
oxidized by t-bOOH and subjected to gel permeation on a calibrated Super- dex 200 column. The effluents were investigated for their: (a) activity by the conventional assay, (b) identity by SDS-PAGE, and (c) shape by electron microscopy (Fig. 3.5 and Fig. 3.6). Reoxidation of the reduced MtAhpC was prevented by equilibrating the column with 20 mM DTT. The reduced protein eluted as a seemingly homogeneous peak with E$_{280}$ paralleling its activity. The eluting material was indistinguishable from authentic MtAhpC in reduced SDS gels displaying a major band complying with the subunit size. Electron micrographs, however, showed a very heterogeneous mixture of ring-shaped, pearl-chain-like, and pearl-like structures (Fig. 3.5 B). The peak fraction eluted with an apparent molecular weight of 224 kDa, which is consistent with the decameric size. The ring structures are considered to represent the pentamers of dimers that were also reported for the AhpC of S. typhimurium (Wood et al., 2002), and the homologous tryparedoxin peroxidases (TXNPx) of Leishmania infantum (Castro et al., 2002) and Trypanosoma brucei (Budde et al., 2003). The “pearls” and open chain structures likely represent the dissociating decamers due to reoxidation after gel filtration.

The oxidized enzyme (Fig. 3.6) eluted with a main peak that was similar to the molecular weight of a dimeric protein. Electron microscopy revealed that the main peak consisted of homogeneous dimeric proteins.

For MtAhpD, gel permeation analyses pointed to a trimeric form independent of the redox state (data not shown). Therefore, redox-dependent conformational changes might determine the accessibility of the reaction centers.

For convenience, steady-state analysis was performed without preincubation of MtAhpC and MtAhpD (see 2.7.5). Lipoamide was not oxidized by t-bOOH alone: the reaction required the addition of both MtAhpD and MtAhpC. None of the components led to a non-specific NADH consumption. In consequence of the previously mentioned oxidative activation the primary Dalziel plot that
shows the reciprocal hydroperoxide concentration at different fixed *Mt*TrxC concentrations (Fig. 3.7 A) does neither yield constant slopes nor are the slopes measured at different cosubstrate concentrations running in parallel. The apparently ‘activated’ parts of the turnover curves for *Mt*AhpC yielded a net forward rate constant $k'_1$, of $1 \times 10^4 \text{M}^{-1}\text{s}^{-1}$ for the reaction with $t$-bOOH, which marks the lower edge of corresponding peroxiredoxin constants (Hofmann *et al*., 2002; Wood *et al*., 2003a) In that context, a $k'_2$ for the reduction by *Mt*AhpD of $2.7 \times 10^6 \text{M}^{-1}\text{s}^{-1}$ which, like the $K_M^{\text{MTP}}$ of 0.23 μM, argues in favour of specific reactivity (Fig. 3.7; Table 3.1).
Fig. 3.5: Oligomerization status of reduced MtAhpC. (A) Elution profile of DTT-reduced MtAhpC in terms of protein content (E_{280}, solid line) and activity (U/ml, −−). (B) Appearance of the peak fraction in electron microscopy (uranylacetate-stained). Arrows indicate ring-shaped and pearl-chain like structures.
Fig. 3.6: Oligomerization status of oxidized MtAhpC. (A) Elution profile of t-bOOH-oxidized MtAhpC in terms of protein content (E$_{280}$, solid line) and activity (U/ml, ---). (B) Appearance of the peak fraction in electron microscopy (uranylacetate-stained).
Substrate turnover by MtAhpC was monitored continuously by NADH consumption in a coupled test system at 25 °C and pH 7.4 with t-butyl hydroperoxide (t-bOOH) as substrate and MtAhpD as cosubstrate. Three sets of data were analyzed according to Dalziel (1957). Results are presented in terms of the general Dalziel-equation for a two-substrate reaction ([E₀]/v = φ₀ + φ₁[ROOH] + φ₂[reductant]; see Table 3.1). (A) Example of primary Dalziel plot showing enzyme-normalized inverse initial velocities ([E₀]/v) dependent on the reciprocal hydroperoxide concentration at different MtAhpD concentrations, kept constant by continuous regeneration. The slopes correspond to φ₁. (B) Secondary Dalziel plot: The ordinate intercepts of (A), i.e. the apparent maximum velocities at [A] = ∞, are plotted against 1/[MtAhpD] for evaluation of Dalziel coefficient φ₂ (slope), limiting K₅₆₆₄MtAhpD (abscissa intercept is 1/K₅₆₆₄MtAhpD) and real maximum velocities (ordinate intercept is φ₀ = [E₀]/V_max). Primary data of three independent analyses, as shown in (A), were used to obtain means and standard deviations.
3.3.2 The thioredoxin-dependent AhpC system

The kinetic analysis of MtAhpC in the system reconstituted by homologous TR and TrxC surprised with irregularities similar to those that had previously been observed with a TXNPx of *L. infantum* (Castro *et al.*, 2002) and *T. brucei* (Budde *et al.*, 2003), and with the MtTPx in this study. Instead of a typical ping-pong pattern that could be expected from the type of catalysis (Hofmann *et al.*, 2002) the primary Dalziel plot does neither yield constant slopes nor appear the slopes measured at different cosubstrate concentrations strictly parallel. In the cases of TXNPx of *L. infantum* and *T. brucei* this kinetic anomaly was interpreted as being indicative of negative cooperativity between subunits. The gel permeation analyses and electron micrographs of reduced MtAhpC (see 3.2.2) yielded an average size of 224 kDa that underscores its decameric nature. The kinetic anomalies of MtAhpC could thus be due to allosteric phenomena as are inferred for other oligomeric peroxiredoxins.

The apparently flatter parts of the turnover curves yielded a $k'_1$ of $2.3 \times 10^4$ M$^{-1}$s$^{-1}$ that is nearly identical to that obtained in the AhpD system, as was expected from the ping-pong-type kinetics of AhpC (Fig. 3.8). Both the $k'_2$ and the $K_M$ characterizing the reactivity and/or affinity to TrxC compare unfavourately with the constants for AhpD by a factor 10 and 20, respectively, as does the $k_{cat}$ (Table 3.1). Yet the relative cellular abundancies of the potential AhpC reductants (see 4.4) qualify MtTrxC as relevant one.
Fig. 3.8: Steady-state-kinetic analysis of MtAhpC with MtTrxC as cosubstrate. Substrate turnover by MtAhpC was monitored continuously by NADPH consumption in a coupled test system at 25 °C and pH 7.4 with t-bOOH as substrate and MtTrxC as cosubstrate. Three sets of data were analyzed according to Dalziel (1957). Results are presented in terms of the general Dalziel-equation for a two-substrate reaction ([E₀/ν = φ₀ + φ₁/[ROOH] + φ₂/reductant]; see Table 3.1). (A) Example of primary Dalziel plot showing enzyme-normalized inverse initial velocities ([E₀/ν] dependent on the reciprocal hydroperoxide concentration at different MtTrxC concentrations, kept constant by continuous regeneration. The slopes correspond to φ₁. Note the biphasic slopes; only the flatter parts were used for data processing. (B) Secondary Dalziel plot: The ordinate intercepts of (A), i.e. the apparent maximum velocities at [A] = ∞, are plotted against 1/[MtTrxC] for evaluation of Dalziel coefficient φ₂ (slope), limiting Kₘ,MtTrxC (abscissa intercept is 1/Kₘ,MtTrxC) and real maximum velocities (ordinate intercept is φ₀ = [E₀]/V_max). Primary data of three independent analyses, as shown in (A), were used to obtain means and standard deviations.
3.3.3 The thiol peroxidase systems

Steady-state kinetics of *MtTPx* activity with *t*-butyl hydroperoxide and *MtTrxB* as substrates (Fig. 3.9) display a classical ping-pong pattern, which can be depicted as a sequence of consecutive reactions,

\[
\text{Trx}_{\text{red}} + \text{TP}_{\text{ox}} \leftrightarrow \text{Trx}_{\text{ox}} + \text{TP}_{\text{red}} \quad (5)
\]

\[
\text{TP}_{\text{red}} + \text{ROOH} \rightarrow \text{TP}_{\text{ox}} + \text{ROH} + \text{H}_2\text{O} \quad (6)
\]

where ROH is the corresponding alcohol. These redox reactions are typically observed with peroxidases.

With *MtTrxC* as substrate, however, the slopes in reciprocal primary plots (Fig. 3.10) appear not to be strictly parallel and show marked deviations from linearity at high peroxide concentrations, particularly pronounced at low cosubstrate levels. To some extent, that could also be observed with the TrxC-dependent AhpC system. As is evident at least from the upper curves in Fig. 3.10 A, the slope is clearly steeper at high hydroperoxide concentrations. Qualitatively, the same phenomenon is seen in the curves obtained at higher TrxC concentrations. Unfortunately, for technical reasons the two phases of the curves could not be assessed with the same accuracy. Only the flatter slopes observed over a wide range of lower hydroperoxide concentrations, could be used for further data processing. Accordingly, the Dalziel coefficients and kinetic constants, obtained from the secondary plot (Fig. 3.10 B) and compiled in Table 3.1, ignore the deviations from the classical ping-pong pattern at extreme substrate concentrations and thus, serve to characterize the enzyme in its predominantly reduced conformation.
Fig. 3.9: Steady-state-kinetic analysis of MtTPx with MtTrxB as cosubstrate. Substrate turnover by MtTPx was monitored continuously by NADPH consumption in a coupled test system at 25 °C and pH 7.4 with t-bOOH as substrate and MtTrxB as cosubstrate. Three sets of data were analyzed according to Dalziel (1957). Results are presented in terms of the general Dalziel-equation for two-substrate reaction ([E_o]/v = ϕ_0 + ϕ_1/[ROOH] + ϕ_2/[reductant]; see Table 3.1). (A) Example of primary Dalziel plot showing enzyme-normalized inverse initial velocities ([E_o]/v) dependent on the reciprocal hydroperoxide concentration at different MtTrxB concentrations, kept constant by continuous regeneration. The slopes correspond to ϕ_1. (B) Secondary Dalziel plot: The ordinate intercepts of (A), i.e. the apparent maximum velocities at [A] = ∞, are plotted against 1/[MtTrxB] for evaluation of Dalziel coefficient ϕ_2 (slope), limiting K_M MtTrxB (abscissa intercept is 1/K_M MtTrxB) and real maximum velocities (ordinate intercept is ϕ_0 = [E_o]/V_max). Primary data of three independent analyses, as shown in (A), were used to obtain means and standard deviations.
Fig. 3.10: Steady-state-kinetic analysis of MtTPx with MtTrxC as cosubstrate. Substrate turnover by MtTPx was monitored continuously by NADPH consumption in a coupled test system at 25 °C and pH 7.4 with t-bOOH as substrate and MtTrxC as cosubstrate. Three sets of data were analyzed according to Dalziel (1957). Results are presented in terms of the general Dalziel-equation for two-substrate reaction ([E0]/v = φ0 + φ1/[ROOH] + φ2/[reductant]; see Table 3.1). (A) Example of primary Dalziel plot showing enzyme-normalized inverse initial velocities ([E0]/v) in dependent on the reciprocal hydroperoxide concentration at different MtTrxC concentrations, kept constant by continuous regeneration. The slopes correspond to φ1. Note the biphasic slopes; only the flatter parts were used for data processing. (B) Secondary Dalziel plot: The ordinate intercepts of (A), i.e. the apparent maximum velocities at [A] = ∞, are plotted against 1/[MtTrxC] for evaluation of Dalziel coefficient φ2 (slope), limiting KM MtTrxC (abscissa intercept is 1/KM MtTrxC) and real maximum velocities (ordinate intercept is φ0 = [E0]/Vmax). Primary data of three independent analyses, as shown in (A), were used to obtain means and standard deviations.
As mentioned previously this kinetic anomaly has also been reported for other oligomeric peroxiredoxins, and for MtAhpC in this study. The phenomenon is interpreted as being indicative of negative cooperativity between subunits. Gel permeation analyses of native MtTPx yielded an average size of \( \sim 36 \) kDa for the oxidized and reduced enzymes, respectively, indicating that two TPx monomers self-associate in solution independent of their redox state (data not shown). The kinetic anomalies of MtTPx could thus be due to allosteric phenomena as inferred for other oligomeric peroxiredoxins, and for MtAhpC in this study.

The peroxidation efficiency of MtTPx is about one order of magnitude higher than that of MtAhpC. With MtTrxB as cosubstrate a \( k'_1 \) value \( 3.3 \times 10^5 \) M\(^{-1}\)s\(^{-1}\) was measured and that appears to be more reliable than the corresponding value of \( 0.9 \times 10^5 \) M\(^{-1}\)s\(^{-1}\) obtained with MtTrxC. In a ping-pong mechanism, the values should be identical but the latter is likely an underestimate due to the deviations from linearity in the reciprocal plots (Fig. 3.10 A). The \( k'_2 \) values of MtTPx for both thioredoxins are similar and slightly higher than MtAhpC for MtTrxC but lower than the MtAhpC/MtAhpD combination. The highest \( V_{\text{max}} \) was obtained for the MtTPx/MtTrxC system.

**Table 3.1: Kinetic constants of MtAhpC and MtTPx.** Rate constants were derived from steady-state analysis; the empirical Dalziel coefficients \( \phi_0, \phi_1 \) and \( \phi_2 \) correspond to the reciprocal values of \( k_{\text{cat}}, k'_1 \) and \( k'_2 \), the latter being net rate constants for the forward reaction of the enzymes with \( t\text{-bOOH} \) and the reductants, respectively.

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Reductant</th>
<th>( k_{\text{cat}} ) [s(^{-1})]</th>
<th>( k'_1 ) [M(^{-1})s(^{-1})]</th>
<th>( k'_2 ) [M(^{-1})s(^{-1})]</th>
<th>( K_{M \text{ROOH}} ) [µM]</th>
<th>( K_{M \text{reductant}} ) [µM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>MtAhpC</td>
<td>MtAhpD</td>
<td>0.63 ± 0.10</td>
<td>0.95 x 10(^4) ± 0.08</td>
<td>2.7 x 10(^6) ± 1.43</td>
<td>65.65</td>
<td>0.23</td>
</tr>
<tr>
<td>MtAhpC</td>
<td>MtTrxC</td>
<td>0.13 ± 0.00</td>
<td>2.3 x 10(^4) ± 0.07</td>
<td>2.5 x 10(^4) ± 0.12</td>
<td>5.64</td>
<td>5.10</td>
</tr>
<tr>
<td>MtTPx</td>
<td>MtTrxB</td>
<td>0.66 ± 0.11</td>
<td>3.4 x 10(^5) ± 0.48</td>
<td>4.6 x 10(^4) ± 0.35</td>
<td>1.95</td>
<td>14.46</td>
</tr>
<tr>
<td>MtTPx</td>
<td>MtTrxC</td>
<td>11.11 ± 0.10</td>
<td>0.9 x 10(^5) ± 0.22</td>
<td>5.8 x 10(^4) ± 0.22</td>
<td>120.68</td>
<td>184.48</td>
</tr>
</tbody>
</table>
3.4 Specificity of MtAhpC and MtTPx for reactive oxygen and nitrogen intermediates

Organic hydroperoxides, peroxynitrite (ONOO−), and other reactive nitrogen and oxygen intermediates produced by macrophages play a role in host defense against invading bacteria (Yu et al., 1999; Nathan and Shiloh, 2000; Akaki et al., 2000; Darrah et al., 2000; Paziak-Domanska et al., 2000; Shiloh and Nathan, 2000). Consequently, many bacterial pathogens have evolved with protection mechanisms against reactive oxygen and nitrogen intermediates (Zahrt and Deretic, 2002).

Like other peroxiredoxins (Hofmann et al., 2002), also MtAhpC and MtTPx reduced a variety of hydroperoxides including H2O2, yet MtAhpC was inactive with phosphatidylcholin hydroperoxide (PCOOH) and MtTPx did not reduce linoleic acid hydroperoxide (LOOH). The percentage activities listed in Table 3.2 may be considered to correspond to relative changes in k′1 values, since they were obtained at identical concentrations of reductants.

<table>
<thead>
<tr>
<th>Table 3.2: Specificity of MtAhpC and MtTPx for hydroperoxide substrates. The enzyme activities with t-butyl hydroperoxide (t-bOOH) were set to 100%. LOOH, PCOOH and COOH mean linoleic acid hydroperoxide, phosphatidylcholin hydroperoxide and cumene hydroperoxide, respectively. *The activities with H2O2 were difficult to estimate due to the basal activity of the TR/Trx system (see 2.7.4).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enzyme</strong></td>
</tr>
<tr>
<td>MtAhpC</td>
</tr>
<tr>
<td>MtTPx</td>
</tr>
</tbody>
</table>
MtAhpC also reduces peroxynitrite (Bryk et al., 2000), which is formed by activated macrophages from ·O₂⁻ and ·NO (Alvarez et al., 2002) and participates in the oxide-dependent killing of M. tuberculosis (St John et al., 2001). The k’₁ value of MtAhpC for peroxynitrite was reported to be 1.33 x 10⁶ M⁻¹s⁻¹. The reactivity of peroxynitrite with MtTPx, that can not be investigated by steady-state kinetics due to its short half-life (< 1 s at pH 7.4; Radi et al., 2000), was evaluated by stopped-flow techniques: Direct monitoring of peroxynitrite decay at 302 nm yielded the expected first order rate constant of 0.3 s⁻¹. In the presence of 15 µM of reduced MtTPx at 25 °C, the initial rate of peroxynitrite reduction was too fast to be reliably measured but entire decay curves reasonably complied with that calculated with second order rate constant k’₁ of 1.2 x 10⁷ M⁻¹s⁻¹ (Fig. 3.11). This fast peroxynitrite reduction was completely inhibited by NEM that is known to inhibit the peroxidatively active thiol of peroxiredoxins (Nogoceke et al., 1997). An independent measurement of k’₁ for the reaction of MtTPx with peroxynitrite by stopped-flow was obtained by measuring the competition with Mn³⁺ porphyrin, that reduces peroxynitrite with a k’₁ of 1.2 x 10⁹ M⁻¹s⁻¹. The rate constant for MtTPx/peroxynitrite interaction calculated therefrom was 1.5 x 10⁷ M⁻¹s⁻¹ and thus is the highest so far observed for any of the enzymes working with sulfur catalysis (Fig. 3.12).
Fig. 3.11: Peroxynitrite reduction by MtTPx. Peroxynitrite (24 µM) decomposition in 100 mM sodium phosphate buffer, 0.1 mM DPTA, pH 7.4, either in the absence (control) or in the presence of reduced MtTPx (15 µM) was followed at 302 nm. The continuous line shows the computer-assisted simulated decay of peroxynitrite (24 µM) in the presence of 15 µM MtTPx assuming a value of $1.2 \times 10^7$ M$^{-1}$s$^{-1}$ for the apparent (pH-dependent) second order rate constant between peroxynitrite and the enzyme. Deviations at times longer than 20 ms reflect the reaction of peroxynitrite with targets in the enzyme other than its reactive thiol (Ferrer-Sueta et al., 1999).
Fig. 3.12: Competition of peroxynitrite-dependent Mn$^{3+}$-TE-2-PyP oxidation by MtTPx. (A) Mn$^{3+}$-TE-2-PyP (7µM) was oxidized by peroxynitrite (2µM) in 50 mM sodium phosphate buffer, 0.1 mM DPTA, pH 7.4 at 25 °C in the absence or presence of different MtTPx concentrations. (B) Plotting the initial rate of Mn$^{3+}$-TE-2-Pyp oxidation against MtTPx concentrations yields a hyperbolic function indicating 50 % inhibition by 5.7 µM MtTPx. With the known rate constant for Mn$^{3+}$-TE-2-PyP a k’1 value of the competing MtTPx is therefrom calculated to be 1.5 x 10⁷ M⁻¹ s⁻¹.
4 Discussion

*M. tuberculosis* does not exhibit the classical oxidative stress responses, with the *oxyR* regulator being absent from its genome (Deretic *et al.*, 1995; Deretic *et al.*, 1997; Cole *et al.*, 1998). In the absence of OxyR-regulated defense, the catalase/peroxidase enzyme encoded by the *katG* gene has been reported to be the only peroxide-inducible gene in *M. tuberculosis*. The isoniazid-resistant strains of *M. tuberculosis* are especially susceptible to oxidative damage due to a non-functional catalase/peroxidase. Therefore, in the absence of a functional *oxyR* response and the malfunctioning *katG*, the tuberculosis bacilli are faced with an unusual situation of survival within the host's macrophages without an effective oxidative stress response. In these strains of *M. tuberculosis*, the *ahpC* gene has been shown to be frequently overexpressed (Wilson and Collins, 1996). AhpC has also been shown to be vital for mycobacterial survival within macrophages (Wilson *et al.*, 1998), and is therefore an attractive drug target.

The second peroxidase system discovered and characterized in this study, the TPx system, seems to play another leading role in peroxide detoxification in *M. tuberculosis*, independent of isoniazid susceptibility, and therefore it too represents an attractive drug target. Recent findings provide support for the importance of an AhpC-independent peroxide detoxifying system like the TPx system. It is likely that KatG, AhpC, and TPx participate in partially overlapping defense activities, and that they undergo stage-specific and/or tissue-specific expression with compensatory activities, as previously noted (Musser, 1995; Sherman *et al.*, 1996; Dhandayuthapani *et al.*, 1996; Heym *et al.*, 1997; Wallis *et al.*, 1999; Wallis *et al.*, 2000; Master *et al.*, 2001). The absence of *oxyR*, the silencing of *ahpC*, and its differential expression and infection-stage-specific induction (Springer *et al.*, 2001) most likely reflect adaptations of various aspects to the infectious cycle of *M. tuberculosis*. For
example, upon transmission to a new host or possibly during initial stages of reactivation from latent infection, the stationary-phase *M. tuberculosis* probably infects naïve, resting monocytes where AhpC may play a role in resistance to the very early, innate cidal mechanisms of macrophages (Master *et al.*, 2002). Once IFN-γ and other protective cytokines become available, AhpC may play a minor role, as indicated by the loss of differential survival between *ahpC*+ and *ahpC*− cells in macrophages (Springer *et al.*, 2001; Master *et al.*, 2002). Thus, at that stage TPx systems may play the lead role in peroxide detoxification.

### 4.1 AhpC and TPx: Members of the peroxiredoxin family

AhpC and TPx are members of the ubiquitous peroxiredoxin (Prx) family within the thioredoxin superfamily of protein folds. Prxs form a family of peroxidases that act on a variety of hydroperoxides using thiols as co-substrates. Until now they were reported to be comprised of glutathione, thioredoxin, tryparedoxin, or the CXXC motifs of bacterial AhpF and AhpD. With most bacterial Prxs, disulfide reduction is achieved by the specialized electron donor AhpF (Poole *et al.*, 2000). In comparison many other Prx systems (both bacterial and eukaryotic), including the AhpC and TPx systems described in this study, receive electrons from a reducing system composed of thioredoxin and thioredoxin reductase (Hofmann *et al.*, 2002; Wood *et al.*, 2003a). To detoxify peroxides, the reduced N-terminal Cys (peroxidatic cysteine), which is conserved in all Prxs, attacks the peroxide -O–O-bond, with concomitant formation of a cysteine sulfenic acid (Cys–SOH) intermediate,

\[
\text{Cys–S}^- + \text{H}^+ + \text{ROOH} \rightarrow \text{Cys–SOH} + \text{ROH}. \quad (7)
\]
It then condenses with a conserved C-terminal Cys (resolving cysteine) to regenerate the stable disulfide bond at the active site (Poole and Ellis, 2002; Baker and Poole, 2003)

\[ \text{Cys–SOH} + \text{RSH} \rightarrow \text{Cys–S–SR} + \text{H}_2\text{O}. \]  

Prxs are divided into three classes: typical 2-Cys Prxs; atypical 2-Cys Prxs; and 1-Cys Prxs. All Prxs share the same basic catalytic mechanism, in which an active-site cysteine (the peroxidatic cysteine) is oxidized to a sulfenic acid by the peroxide substrate. The recycling of the sulfenic acid back to a thiol is what distinguishes the three enzyme classes.

The typical 2-Cys Prxs are the largest class of Prxs and are identified by the conservation of their two redox-active cysteines, the peroxidatic cysteine (generally near residue 50) and the resolving cysteine (near residue 170) (Hofmann et al., 2002). Typical 2-Cys Prxs are obligate homodimers containing two identical active sites (Hirotsu et al., 1999; Alphey et al., 2000; Schroeder et al., 2000; Wood et al., 2002). In the second step of the peroxidase reaction, the peroxidatic cysteine sulfenic acid from one subunit is attacked by the resolving cysteine located in the C-terminus of the other subunit. This condensation reaction results in the formation of a stable intersubunit disulfide bond, which is then reduced by one of several cell-specific disulfide oxidoreductases (e.g. thioredoxin, AhpF, tryparedoxin or AhpD (Nogoceke et al., 1997; Poole et al., 2000; Bryk et al., 2002)), completing the catalytic cycle.

The second class of Prxs are the atypical 2-Cys Prxs, which have the same mechanism as typical 2-Cys Prxs but are functionally monomeric (Seo et al., 2000; Declercq et al., 2001; Baker and Poole, 2003). In these Prxs, both the peroxidatic cysteine and its corresponding resolving cysteine are contained within the same polypeptide, with the condensation reaction resulting in the formation of an intramolecular disulfide bond. Although the resolving cys-
The last class of Prxs, the 1-Cys Prxs, conserve only the peroxidatic cysteine and do not contain a resolving cysteine (Choi et al., 1998). Their cysteine sulfenic acid generated through reaction with peroxides is presumably reduced by a thiol-containing electron donor. In few examples, the donor has been shown to be glutathione (GSH) (Hofmann et al., 2002), but the identity of the redox partner is not yet clear in most cases.

4.2 AhpC and TPx homologues

AhpC has sequence homology to the two cysteine containing AhpC proteins from other organisms and seems to belong to the typical 2-Cys Prxs. It has a higher similarity to the Gram-positive (M. bovis, M. smegmatis, Corynebacterium diphtheriae, and Streptomyces viridosporus) than to the Gram-negative (E. coli, S. typhimurium, Bacillus subtilis, and Staphylococcus aureus) AhpC proteins. Interestingly the M. tuberculosis AhpC possesses three Cys residues, two located in close vicinity in the C-terminal region, at positions 174 and 176. The conserved N-terminal Cys residue is located at position 61. Both the Cys-174 and Cys-176 residues can form a disulfide bond with the conserved N-terminal Cys residue (Chauhan and Mande, 2001) and all the three Cys residues are important for activity. Cys-61 and Cys-174 play a critical role but Cys-176 is also involved in the catalytic cycle (Hillas et al., 2000; Chauhan and Mande, 2002).

Homologues of TPx are distributed throughout most or all Gram-positive and Gram-negative bacteria, but biochemical analyses have been limited primarily to E. coli TPx. EcTPx is part of an oxidative stress defense system that uses equivalents from thioredoxin and thioredoxin reductase to reduce alkyl hydroperoxides. TPx homologues typically contain three Cys residues,
Cys-93, Cys-80, and Cys-60 in MtTPx, and the latter residue aligns with the N-terminal active site Cys of other peroxidases in the Prx family.

4.3 Structural and conformational properties of MtAhpC and MtTPx

AhpC and TPx are both members of the Prx family; however, the two *M. tuberculosis* Prx members are highly divergent from one another and are representatives of two distinct Prx subfamilies: typical 2-Cys Prxs (MtAhpC), and atypical 2-Cys Prxs (MtTPx) (Hofmann et al., 2002; Wood et al., 2003a). Generally, the active site of typical 2-Cys Prxs contains a disulfide bond composed of a conserved N-terminal Cys (Cys-46 from *S. typhimurium* AhpC) and the C-terminal Cys (Cys-165 from *S. typhimurium* AhpC) from the other subunit of the parallel, but directionally opposite, dimer (Ellis and Poole, 1997). Crystal structures of reduced (tryparedoxin peroxidase from *Crithidia fasciculata*), oxidized (HBP23 from rat) and overoxidized (TPxB from human) typical 2-Cys Prx homologues showed that reduction of the disulfide bridge induces a conformational change in the quaternary structure from a dimeric to a decameric form or *vice versa* (Hirotsu et al., 1999; Alphey et al., 2000; Schroeder et al., 2000). Although oligomerization seems to be a general property of 2-Cys Prxs, the *in vivo* parameters inducing oligomerization and its function are unknown. Low or high ionic strength, acidic pH, and reducing or oxidizing conditions are reported to promote oligomerization but differ in their effects upon various 2-Cys Prxs (Chauhan and Mande, 2001; Wood et al., 2002; Budde et al., 2003; König et al., 2003). Gel permeation analyses and electron microscopy studies provide evidence for a redox-dependent process in *M. tuberculosis* AhpC whereby reduced decamers disassociate very rapidly into dimers upon oxidation. That was also reported for *S. typhimurium* AhpC (Wood et al., 2002). A facilitated interaction of MtAhpC with its reductant MtAhpD due to redox-dependent conforma-
tional changes and ‘activation’ could explain the unusual lag phase in time progression curves (see Fig. 3.4).

Atypical 2-Cys Prxs like *MtTPx* are proposed to be functionally monomeric (Declercq *et al.*, 2001). For the *E. coli* homologue of TPx it was reported that it does not form the hallmark intersubunit disulfide linkage of typical 2-Cys Prxs, and instead Cys-61 (Cys-60 from *MtTPx*) links with Cys-95 (Cys-93 from *MtTPx*) through an intra-molecular disulfide bond. Cys-95 participates as a disulfide partner and is functionally equivalent to the resolving cysteine that resides in another subunit of the more common typical 2-Cys Prxs. Based on the structural data of *C. fasciculata* TXNPx (Hofmann *et al.*, 2001) and other peroxiredoxins (Hirotsu *et al.*, 1999; Schroeder *et al.*, 2000) a model of TPx from *M. tuberculosis* was created, which provides evidence for a similar mechanism for *MtTPx* (Fig. 4.1). Gel permeation analyses revealed a homodimeric nature of *MtTPx*, as was also shown for *EcTPx* by ultracentrifugation analyses (Baker and Poole, 2003). 1-Cys Prxs are also functionally monomeric, but form homodimers at protein concentrations > 1 mg/ml (Choi *et al.*, 1998) and therefore, the formation of *MtTPx* dimers could occur due to high protein concentration. In conclusion, unlike the more common typical 2-Cys Prxs, which operate by an intersubunit disulfide mechanism, *MtTPx* contains a redox-active intrasubunit disulfide bond yet is homodimeric in solution.
Fig. 4.1: Model of MtTPx (upper panel) and a TPx/Trx catalytic intermediate (lower panel). Upper panel: Conformation of oxidized MtTPx, as modeled into the structure of C. fasciculata TXNPx. The intramolecular disulfide bond is shown as balls and sticks. Lower panel: Model of a catalytic intermediate demonstrating potential TPx/Trx interactions. The solvent exposed C34 of the MtTrxC (ribbon diagram) has reacted with the accessible C93 (resolving cysteine) of the MtTPx. Surface charges are shown in red (negative) and blue (positive), residue designations in red.
The kinetic analyses of the TrxC/AhpC and TrxC/TPx system did not comply with a simple ping-pong mechanism, as is common for peroxidases. In other words, oxidation of the enzyme by the hydroperoxide substrate followed by an independent reaction with the reductant (Dalziel, 1957; Ursini et al., 1995; Flohé and Brigelius-Flohé, 2001; Hofmann et al., 2002). Particularly intriguing were deviations from linearity in the double-reciprocal plots (Fig. 3.8 A; Fig. 3.10 A). Such irregularities had already been reported for the kinetic behaviour of the mitochondrial TXNPx of Leishmania infantum (Castro et al., 2002) and the TXNPx of Trypanosoma brucei brucei (Budde et al., 2003). In those cases, the phenomenon was interpreted as negative cooperativity between subunits. Our kinetic and morphological data support the concept of negative cooperativity to be valid also for MtAhpC and MtTPx. Taking into account the growing number of Prxs with an irregular kinetic behaviour, not following strictly linear Lineweaver-Burk or Dalziel plots might rather be the rule than the exception for Prxs.

It remains an intriguing question as to what extent the cooperativity concept may be extended to other 2-Cys Prxs. Certainly there are qualitative differences: with TXNPxs of L. infantum and T. brucei brucei, for instance, a dimer to decamer transition was reported to be induced by oxidation (Castro et al., 2002; Budde et al., 2003). In contrast, with AhpC of M. tuberculosis and S. typhimurium (Wood et al., 2002) the decamer is stabilized by reduction. In general, however, the 2-Cys Prxs qualify as potentially cooperative proteins. Since the early conceptual thoughts as to why proteins form oligomers that communicate with each other, cooperativity has been considered as a tool for metabolic regulation (Monod et al., 1965; Koshland, 1970; Stadtman, 1970). The Prxs appear to support that view. If not in control of peroxide detoxification Prxs are evidently involved in regulating signaling cascades or metabolic processes (Hofmann et al., 2002; Wood et al., 2003b). The evident cooperative potential of the Prxs deserves particular attention when the biological function of this novel family of proteins is to be explored.
4.4 Physiological relevance of the MtAhpC and MtTPx systems

The kinetic constants compiled in Table 3.1 and derived from Fig. 3.11 and Fig. 3.12 allow the estimation of turnover rates for the different mycobacterial peroxidase systems (Fig. 4.2), by means of the general rate equation for two-substrate ping-pong mechanisms,

\[
\frac{[E_0]}{v} = \phi_0 + \phi_1/[\text{ROOH}] + \phi_2/\text{[reductant]}
\] (9)

if, as a first approximation, the peculiarities of peroxiredoxin kinetics at extreme substrate concentrations are ignored. Unfortunately, however, the concentrations of the enzymes appear to vary between strains and substrate concentrations can only be roughly estimated. At low peroxide level and high supply of reductants, as is commonly assumed for unstressed situations, the turnover depends on the level of reduced peroxidase that should approximately equal \([E_0]\), on \(k_1'\) and on the peroxide concentration

\[
v = k_1' [E_{\text{red}}] [\text{ROOH}].
\] (10)

AhpC is hardly detected in most of the \(katG^+\) strains of \(M. tuberculosis\) and \(M. marinum\), but is easily found in \(M. smegmatis\) and \(M. bovis\) BCG. In contrast, MtTPx is consistently seen in proteomes of \(M. tuberculosis\). Its concentration may be estimated to be much higher than AhpC (Pagan-Ramos et al., 1998; Jungblut et al., 1999; Mollenkopf et al., 1999; Springer et al., 2001). Being the dominant peroxiredoxin and having a higher \(k_1'\) than AhpC, MtTPx may definitely be rated as the more relevant enzyme.

Under \(H_2O_2\) stress the reductant capacity may become limiting according to

\[
v = k_2' [E_{\text{ox}}] \text{[reductant]}. \] (11)

The concentration of the reductants is linked in a complex manner to the NADH and NADPH pools and depends on the speed of regenerating en-
zymes and the pool size of the reductant, only the latter being easily estimated. AhpD is identifiable in *M. tuberculosis* proteomes as a minor spot corresponding to a low molarity level. In comparison, *Mt*TrxB, although known by its sequence and characterized here as a specific substrate of MtTPx, so far could not be identified in proteomes. To the contrary, *Mt*TrxC is always seen as a major protein in all *M. tuberculosis* strains investigated. *Mt*TR is a medium spot in all mycobacterial proteomes analyzed (Nagai *et al.*, 1991; Sonnenberg and Belisle, 1997; Weldingh *et al.*, 1998; Jungblut *et al.*, 1999; Mollenkopf *et al.*, 1999; Rosenkrands *et al.*, 2000a; Rosenkrands *et al.*, 2000b). Thus, because of their high reduction capacities, the *Mt*TR/TrxC-mediated detoxification systems should become particularly relevant under conditions of oxidative stress.

Considering both rate constants and capacities, NADPH-driven H$_2$O$_2$ reduction by the *Mt*TR/*Mt*TrxC/*Mt*AhpC and the *Mt*TR/*Mt*TrxC/*Mt*TPx systems should be at least as efficient as the NADH-driven, AhpD/AhpC-mediated system in coping with H$_2$O$_2$ challenge in *katG* strains. Both peroxiredoxin-type peroxidases, however, may also satisfy special antioxidant requirements in *katG* strains by acting on a broad spectrum of hydroperoxides. *Mt*AhpC reduces complex lipid hydroperoxides with complementary efficiencies and *Mt*TPx can even compete with catalase in peroxynitrite reduction (Table 3.2; Fig. 3.11 and Fig. 3.12). Therefore, both *Mt*AhpC and *Mt*TPx complement catalase in antioxidant defense of *M. tuberculosis* as do broad spectrum selenoperoxidases, such as GPx-1, in the host (Flohé and Brigelius-Flohé, 2001; Fig. 4.2 A), where the peroxiredoxins fall short in catalytic efficiencies and are more likely involved in specific redox regulation of metabolic processes (Hofmann *et al.*, 2002; Wood *et al.*, 2003b). In mycobacteria, being devoid of the GSH-dependent detoxification system, the peroxiredoxins should significantly contribute to the pathogen’s resistance to the oxidative and nitrosative stress exerted by the innate immune response.
Fig. 4.2: Hydroperoxide detoxifying systems in *M. tuberculosis*. (A) The main route of mammalian hydroperoxide reduction is shown for comparison. (B) NADPH-driven hydroperoxide reduction by AhpC, mediated by TR and Trx. (C) NADH-driven and AhpD-mediated hydroperoxide reduction by AhpC according to Bryk et al. (2002). (D) NADPH-driven hydroperoxide reduction by TPx, mediated by TR and TrxB or TrxC, respectively. AhpC, alkyl hydroperoxide reductase subunit C; AhpD, alkyl hydroperoxide reductase subunit D; GPx-1, type-1 glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; GSSG, oxidized glutathione; Lpd, dihydrolipoamide dehydrogenase; SucB, dihydrolipoamide succinyltransferase; TPx, thiol peroxidase; TR, thioredoxin reductase; Trx, thioredoxin.
4.5 AhpC and TPx are potential drug targets

Tuberculosis has re-emanated as a growing global health problem not only because of the lack of proper therapeutic agents for its treatment but also due to the development of drug-resistant strains. The disease still continues its ravenous journey across the world killing young and middle-aged adults faster than any disease other than AIDS. Despite the widespread use of the bacillus Calmette-Guérin vaccine and the availability of antibiotics against *M. tuberculosis*, it is estimated that in 1997 there were approximately eight million new cases of tuberculosis and nearly two million deaths due to the disease (Dye *et al.*, 1999). The emergence of MDR strains of the deadly pathogen render the current mode of treatment very difficult and in many cases completely ineffective. Thus, newer and more efficient anti-TB drugs are desperately needed. The unravelling of the *M. tuberculosis* genome sequence (Cole *et al.*, 1998), gives new dimensions to anti-TB drug research. It has initiated a hunt for genes of interest either for vaccine development, as candidates for protective antigens or as molecular targets to screen for inhibitors that might prove useful as antituberculous drugs. New methods for identifying the enzymes/proteins involved in essential biochemical pathways of *M. tuberculosis* are now available. The discovery of novel hydroperoxide detoxifying pathways in the present study is a promising example of how to make use of genome information. A better understanding of the underlying molecular mechanisms of *M. tuberculosis* virulence and pathogenicity will hopefully lead to the development of new therapies against tuberculosis.

In my view, there are two main ways to approach the identification of potential new drug targets from the TB genome:

- To select for targets that are conserved amongst different species of bacteria but poorly conserved or alternatively unconserved in humans.
Targeting such molecules may lead to broad-spectrum antimicrobial agents.

- To identify potential targets that are unique to *M. tuberculosis* for developing specific anti-TB drugs.

In the present study the second approach was pursued. The different peroxidase systems described here were discovered by systematic screening of the *M. tuberculosis* genome sequence for homologues of AhpF, thioredoxin-related proteins and peroxiredoxins. The isolated gene products were functionally analyzed and tested with regard to the relevance for mycobacterial peroxide detoxification. The *in vitro* recombination of the gene products resulted in two novel redox cascades. Due consideration of the *in vivo* concentrations of the participating enzymes and their kinetic efficiency, qualify the thioredoxin-dependent AhpC and TPx systems as relevant ones. Thereby, *Mt*AhpC and *Mt*TPx, and their supportive enzymes *Mt*TR and *Mt*TrxC, deserve interest as potential targets for the design of anti-TB agents. Specific inhibitors of those enzymes should have tuberculostatic or even tuberculocidal effects and could serve as a powerful tool in fighting against INH-resistant and/or MDR strains.
5 Summary

Drug resistance and virulence of *M. tuberculosis* are in part related to the pathogen’s antioxidant defense systems. *KatG*− strains are resistant to the first line tuberculostatic isoniazid but they need to compensate their catalase deficiency by alternative peroxidase systems to remain virulent. So far only NADH-driven and AhpD-mediated hydroperoxide reduction by AhpC has been implicated as such a virulence-determining mechanism. In search of more likely metabolic links of AhpC, the genome of *M. tuberculosis* was screened for homologues of AhpF, thioredoxin-related proteins and peroxiredoxins. The genes were expressed heterologously in *E. coli* or *M. smegmatis* and purified to homogeneity. By means of those tools, two novel pathways were discovered that underscore the importance of the thioredoxin system for antioxidant defense in *M. tuberculosis*. They are: (1) NADPH-driven hydroperoxide reduction by AhpC that is mediated by thioredoxin reductase and thioredoxin C and (2) hydroperoxide reduction by the atypical peroxiredoxin TPx that equally depends on thioredoxin reductase but can use both thioredoxin B and C. According to kinetic analyses of hydroperoxide and peroxynitrite reduction and estimated enzyme levels, the redox cascade comprising thioredoxin reductase, thioredoxin C and TPx should be the most efficient system *in situ* to protect *M. tuberculosis* against oxidative and nitrosative stress.
6 References


7 Appendix

7.1 Abbreviations

Å Ångström

$A_x$ absorption at x nm

AhpC alkyl hydroperoxide reductase subunit C

AhpD alkyl hydroperoxide reductase subunit D

AhpF alkyl hydroperoxide reductase subunit F

AIDS acquired immune deficiency syndrome

AFB acid-fast bacilli

APS ammoniumperoxodisulfate

ATCC American Type Culture Collection

bp base pair

BCG Bacille Calmette Guérin

BD Becton Dickinson

BSA bovine serum albumine

COOH cumene hydroperoxide
Da

dean

dest

DNA

dNTP

DOTS

DPTA

DSMZ

DTT

Ex

Ec

EDTA

EFTEM

Fig

GBF

GPx-1

Dalton

deionized

destilled

deoxyribonucleic acid

deoxyribonucleoside triphosphate

directly observed treatment short-course

diethylene-triamine-pentaacetic acid

German Culture Collection of Microorganisms and Cell Cultures

dithiothreitol

extinction at x nm

Escherichia coli

ethylenediaminetetraacetic acid

energy-filtered transmission electron microscope

figure

German Research Centre for Biotechnology

type-1 glutathione peroxidase
GR  glutathione reductase
GSH  glutathione

HBP23  heme binding protein 23 kDa
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIV  human immunodeficiency virus
HSP  heat shock protein

i.e.  in example

IFN-γ  interferon-γ
INH  isoniazid

InhA/inhA  acyl carrier protein-enoyl reductase
IPTG  isopropyl-β-D-thiogalactopyranoside

KatG/katG  catalase peroxidase
kDa  Kilodalton

LB  Luria Bertani medium
LOOH  13-hydroperoxy octadecadienoic acid hydroperoxide
Lpd  dihydrolipoamide dehydrogenase
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>LT-α3</td>
<td>lymphotoxin-α3</td>
</tr>
<tr>
<td>MALDI-TOF</td>
<td>matrix-assisted laser desorption and ionization time-of-flight</td>
</tr>
<tr>
<td>MDR</td>
<td>multi-drug-resistant</td>
</tr>
<tr>
<td>MIC</td>
<td>minimum inhibiting concentration</td>
</tr>
<tr>
<td>Mn\textsuperscript{3+}-TE-2-PyP</td>
<td>Mn\textsuperscript{3+}-meso-tetrakis[(N-ethyl)pyridinium-2-yl]porphyrin</td>
</tr>
<tr>
<td>MSB</td>
<td>master seed bank</td>
</tr>
<tr>
<td>Mt</td>
<td><em>Mycobacterium tuberculosis</em></td>
</tr>
<tr>
<td>MycR</td>
<td>mycothiol reductase</td>
</tr>
<tr>
<td>MSH</td>
<td>mycothiol</td>
</tr>
<tr>
<td>NADH</td>
<td>nicotinamide adenine dinucleotide</td>
</tr>
<tr>
<td>NADPH</td>
<td>nicotinamide adenine dinucleotide phosphate</td>
</tr>
<tr>
<td>Ndh/ndh</td>
<td>NADH dehydrogenase</td>
</tr>
<tr>
<td>NEM</td>
<td>N-ethylmaleimid</td>
</tr>
<tr>
<td>NTA</td>
<td>nitrilotriacetic acid</td>
</tr>
<tr>
<td>OD\textsubscript{x}</td>
<td>optical density at x nm</td>
</tr>
<tr>
<td>ORF</td>
<td>open reading frame</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>OxyR/oxyR</td>
<td>oxidative stress regulator</td>
</tr>
<tr>
<td>PAGE</td>
<td>polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>PCOOH</td>
<td>phosphatidylcholin hydroperoxide</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>Prx</td>
<td>peroxiredoxin</td>
</tr>
<tr>
<td>PVDF</td>
<td>polyvinylidendifluoride</td>
</tr>
<tr>
<td>RMP</td>
<td>rifampin/rifampicin</td>
</tr>
<tr>
<td>RNI</td>
<td>reactive nitrogen intermediates</td>
</tr>
<tr>
<td>ROI</td>
<td>reactive oxygen intermediates</td>
</tr>
<tr>
<td>rpm</td>
<td>rounds per minute</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SucB</td>
<td>dihydroliponamide succinyl-transferase</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TBE</td>
<td>tris-borate EDTA</td>
</tr>
<tr>
<td>t-bOOH</td>
<td>tert-butyl hydroperoxide</td>
</tr>
</tbody>
</table>
TEMED  N,N,N',N'-tetramethylethylenediamine

TNF-α  tumour-necrosis factor-α

TPx  thiol peroxidase

TR  thioredoxin reductase

Trx  thioredoxin

TXNPx  tryparedoxin peroxidase

UNAM  Universidad Nacional Autónoma de México

vol  volume

WHO  World Health Organization

7.2 Abbreviations of nucleotides and amino acids

Table 7.1: Abbreviations of nucleotides

<table>
<thead>
<tr>
<th>nucleotide</th>
<th>abbreviations</th>
</tr>
</thead>
<tbody>
<tr>
<td>adenine</td>
<td>A</td>
</tr>
<tr>
<td>cytosine</td>
<td>C</td>
</tr>
<tr>
<td>guanine</td>
<td>G</td>
</tr>
<tr>
<td>uracile</td>
<td>U</td>
</tr>
<tr>
<td>thymine</td>
<td>T</td>
</tr>
</tbody>
</table>
### Table 7.2: Abbreviations of amino acids

<table>
<thead>
<tr>
<th>amino acid</th>
<th>1 letter code</th>
<th>3 letter code</th>
</tr>
</thead>
<tbody>
<tr>
<td>alanine</td>
<td>Ala</td>
<td>A</td>
</tr>
<tr>
<td>arginine</td>
<td>Arg</td>
<td>R</td>
</tr>
<tr>
<td>asparagine</td>
<td>Asn</td>
<td>N</td>
</tr>
<tr>
<td>aspartic acid</td>
<td>Asp</td>
<td>D</td>
</tr>
<tr>
<td>cysteine</td>
<td>Cys</td>
<td>C</td>
</tr>
<tr>
<td>glutamine</td>
<td>Gln</td>
<td>Q</td>
</tr>
<tr>
<td>glutamic acid</td>
<td>Glu</td>
<td>E</td>
</tr>
<tr>
<td>glycine</td>
<td>Gly</td>
<td>G</td>
</tr>
<tr>
<td>histidine</td>
<td>His</td>
<td>H</td>
</tr>
<tr>
<td>isoleucine</td>
<td>Ile</td>
<td>I</td>
</tr>
<tr>
<td>leucine</td>
<td>Leu</td>
<td>L</td>
</tr>
<tr>
<td>lysine</td>
<td>Lys</td>
<td>K</td>
</tr>
<tr>
<td>methionine</td>
<td>Met</td>
<td>M</td>
</tr>
<tr>
<td>phenylalanine</td>
<td>Phe</td>
<td>F</td>
</tr>
<tr>
<td>proline</td>
<td>Pro</td>
<td>P</td>
</tr>
<tr>
<td>serine</td>
<td>Ser</td>
<td>S</td>
</tr>
<tr>
<td>threonine</td>
<td>Thr</td>
<td>T</td>
</tr>
<tr>
<td>tryptophan</td>
<td>Trp</td>
<td>W</td>
</tr>
<tr>
<td>tyrosine</td>
<td>Tyr</td>
<td>Y</td>
</tr>
<tr>
<td>valine</td>
<td>Val</td>
<td>V</td>
</tr>
</tbody>
</table>
Danksagung

Die vorliegende Arbeit wurde unter der wissenschaftlichen Anleitung von Prof. Dr. Dr. h.c. L. Flohé und Prof. Dr. M. Singh in der Abteilung für der Biochemie der Technischen Universität Braunschweig an der Gesellschaft für Biotechnologische Forschung mbH (GBF) angefertigt.

Herrn Prof. Dr. Leopold Flohé und Herrn Prof. Dr. Mahavir Singh danke ich für die Überlassung der interessanten Themenstellung, ihre ständige Hilfs- und Diskussionsbereitschaft und für das große Interesse, das sie meiner Arbeit entgegen gebracht haben.

Bei Heike Budde und Marcelo Comini möchte ich mich für die ausgesprochene Hilfsbereitschaft bedanken. Das fröhliche und familiäre Laborklima hat maßgeblich zum guten Gelingen der Arbeit beigetragen.

An dieser Stelle sei auch allen Kollegen der “TU-AG” für die freundliche Unterstützung gedankt.


Karin Plank-Schumacher und Claudia Wylegalla gilt mein Dank für die zahlreichen DNA-Sequenzierungen. Rita Getzlaff danke ich für die Proteinsequenzierungen und Ulrich Menge für die tatkräftige Unterstützung bei der Mycothiol-Isolation.

Birgit Hofmann und Hans-Jürgen Hecht danke ich für die Hilfestellung bei allen strukturbioologischen Fragestellungen. Heinrich Lünsdorf danke ich für die elektronenmikroskopischen Aufnahmen. Madia Trujillo und Rafael Radi gilt mein Dank für die unkomplizierte Zusammenarbeit und die Durchführung

Besonders danke ich Ina für ihre tatkräftige Hilfe und moralische Unterstützung während der gesamten Zeit meiner Promotion, die oft das Arbeiten erleichtert haben.

Besonderer Dank gilt auch meinen Eltern, die mich in dieser Zeit nach allen Kräften unterstützt und mir in jeder Situation zur Seite standen.

Diese Arbeit wurde finanziell durch die Deutsche Forschungsgemeinschaft und die GBF unterstützt.
Lebenslauf

Name
Timo Jäger

Geburtsdatum und -ort
10.10.1974 in Gießen

Staatsangehörigkeit
deutsch

Familienstand
ledig

Schulausbildung
1981 - 1983: Grundschule Pohlheim-Holzheim
1983 - 1985: Grundschule Braunschweig-Völkenrode
1985 - 1987: Orientierungsstufe Wendeburg
1987 - 1990: Martino-Katharineum, Gymnasium, Braunschweig
1990 - 1994: Liebigschule, Gesamtschule, Gießen

Schulabschluß
Abitur am 10.06.1994

Studium
01.10.1994 - 31.03.2000: Technische Universität Braunschweig,
Fachrichtung Biologie-Diplom,
Hauptfach: Mikrobiologie,
Nebenfächer: Zellbiologie, Biochemie/Biotechnologie
Studienabschluß
Diplom am 04.12.1999,
Diplomarbeit „Die L-Alanin-Dehydrogenase und die Alkylhydroperoxid-Reduktase von pathogenen Mykobakterien: Untersuchungen zum Einsatz in der Diagnostik und Knockout-Versuche“

Promotionsarbeit
seit 01.01.2000: Abteilung für Biochemie der Technischen Universität Braunschweig an der Gesellschaft für Biotechnologische Forschung mbH (GBF), Braunschweig